Blog

AVLAYAH Approved: For Hunter Syndrome Families, This FDA Decision Hits Different

April 7, 2026

📌 The essentials On March 25, 2026, the FDA granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm, Denali Therapeutics) for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, MPS II) in pediatric patients weighing at least 5 kg, when initiated prior to advanced neurologic impairment. This is the first FDA-approved therapy specifically designed to cross the blood-brain barrier, and the first new FDA-approved treatment for Hunter syndrome in nearly 20 years. The clinical basis: Phase 1/2 trial (NCT02055118) in 47 patients (ages 0.3 to 13 years, median age 5), showing 91% reduction in CSF heparan sulfate (95% CI: 89% to 92%) by week 24, with 93% of treated patients (41 of 44) reaching CSF HS levels within the range of unaffected individuals. Secondary endpoints included improvements in Vineland-3 adaptive behavior scores, Bayley Scales of Infant and Toddler Development (BSID-III), liver volume normalization, and hearing. Accelerated approval context: continued approval may be contingent on the ongoing Phase 2/3 COMPASS confirmatory trial, which randomizes patients 2:1 to AVLAYAH versus idursulfase (standard of care) over 96 weeks. A Rare Pediatric Disease Priority Review Voucher was granted alongside the approval.

When the National MPS Society shared news of the AVLAYAH approval on social media, the comments section filled with responses from parents who had been tracking this program for years. “We’ve been waiting 18 years for this.” That context is worth keeping in mind as we go through what this approval actually means, and what it does not yet answer.

AVLAYAH (tividenofusp alfa-eknm), developed by Denali Therapeutics, received FDA accelerated approval on March 25, 2026, as a treatment for Hunter syndrome (MPS II). It is the first new therapy for this condition in nearly two decades. It is also the first therapy ever designed to reach the brain.

What Is Hunter Syndrome?

Hunter syndrome (MPS II) is a rare, X-linked lysosomal storage disorder caused by a deficiency of the enzyme iduronate 2-sulfatase (IDS). Without sufficient IDS, complex sugars called glycosaminoglycans (GAGs), specifically heparan sulfate and dermatan sulfate, accumulate in cells throughout the body.

The condition is estimated to affect fewer than 500 people in the United States, almost all of them male. The consequences compound over time: developmental delays, cognitive regression, hearing loss, progressive joint stiffness, and organ dysfunction. The disease has a neuronopathic form, where the accumulation affects the brain and causes progressive neurological deterioration, and a non-neuronopathic form with primarily somatic (body) manifestations.

The existing treatment, Elaprase (idursulfase, Takeda), was approved in 2006. It has been the only FDA-approved therapy for Hunter syndrome for nearly 20 years. It reduces GAG accumulation in peripheral tissues and improves some physical symptoms, but it does not meaningfully cross the blood-brain barrier. Families managing the neuronopathic form have watched their children lose cognitive and developmental ground knowing that existing enzyme replacement therapy simply could not reach where the damage was happening.

What AVLAYAH Does Differently: The Blood-Brain Barrier Problem

The blood-brain barrier (BBB) is a highly selective physical barrier formed by the specialized endothelial cells lining brain capillaries. It protects the central nervous system from pathogens and toxins but also blocks the passage of most large molecules, including therapeutic proteins. Most enzyme replacement therapies, regardless of how effective they are in peripheral tissues, cannot reach the brain in therapeutic concentrations.

Denali’s approach to this problem is their TransportVehicle (TV) platform, which engineers therapeutic molecules to exploit a transport system the brain’s own blood vessels already use. The transferrin receptor (TfR1) is expressed on brain endothelial cells and mediates the transport of iron-bound transferrin across the BBB through receptor-mediated transcytosis. By engineering a therapeutic molecule to bind TfR1 with carefully tuned affinity, Denali can hitch the molecule across the BBB using this existing transport pathway.

Tividenofusp alfa consists of the IDS enzyme fused to an antibody fragment targeting TfR1. After intravenous infusion, the molecule circulates through the bloodstream, reaches brain blood vessels, binds to TfR1 on those vessels, and is transported into the brain, where the enzyme can then begin reducing the heparan sulfate accumulation that drives neurological deterioration. The same molecule also distributes to peripheral tissues, addressing the somatic manifestations of the disease through a standard intravenous infusion route, without requiring intrathecal (spinal) administration.

No spinal tap required. That is not a minor practical detail for pediatric patients and their families.

The Phase 1/2 Trial: What the Data Shows

The FDA accelerated approval is based on data from a Phase 1/2 international, multicenter, open-label trial (NCT02055118) published in the New England Journal of Medicine on January 1, 2026. The trial enrolled 47 patients with Hunter syndrome, including both enzyme replacement therapy-naive patients (n=15) and previously treated patients (n=32). Ages ranged from 0.3 to 13 years, with a median age of 5.

The primary objective was safety and tolerability. Secondary objectives evaluated CNS and peripheral effects through multiple biomarker and clinical measures.

Endpoint	Result	Detail
CSF heparan sulfate reduction at week 24	91% reduction from baseline	95% CI: 89% to 92%
Patients reaching normal CSF HS range at week 24	93% (41 of 44 evaluable)	Levels within range of individuals without Hunter syndrome
Vineland-3 adaptive behavior	Improvements observed	Measures real-world functional skills: communication, daily living, socialization
BSID-III developmental scales	Improvements observed	Bayley Scales of Infant and Toddler Development
Liver volume	Normalization observed	Hepatomegaly is a characteristic feature of MPS II
Hearing	Improvements observed	Hearing loss is a common complication of MPS II
Most common adverse reaction	Infusion-related reactions	Consistent with other enzyme replacement therapies

Source: Denali Therapeutics FDA approval press release, March 25, 2026. New England Journal of Medicine. January 1, 2026. Phase 1/2 tividenofusp alfa in MPS II.

The 91% reduction in CSF heparan sulfate with 93% of patients reaching the normal range is a striking biomarker result for a rare disease study of this size. The secondary signals in adaptive behavior, developmental assessments, liver volume, and hearing add clinical texture to the biomarker data, suggesting the molecular effect is translating into meaningful functional signals across multiple organ systems.

Dr. Joseph Muenzer, MD, PhD, Director of the Muenzer MPS Research and Treatment Center and the Bryson Distinguished Professor in Pediatric Genetics at the University of North Carolina at Chapel Hill, described the approval as a breakthrough advance and the first therapeutic innovation for the Hunter syndrome community in nearly 20 years in a statement accompanying the approval announcement.

What accelerated approval means here, and why the distinction matters Accelerated approval means the FDA accepted CSF heparan sulfate reduction as a surrogate endpoint reasonably likely to predict clinical benefit, a common pathway for rare diseases where full outcome trials would take years and withholding a promising therapy during that time carries its own cost. AVLAYAH still needs to demonstrate in the ongoing Phase 2/3 COMPASS study that reducing heparan sulfate actually slows or prevents cognitive decline at the clinical level. That is a meaningful distinction for families making treatment decisions right now: the biomarker effect is real and dramatic, but the evidence that it translates into preserved or improved cognitive and neurological function will come from the COMPASS study, not from the Phase 1/2 data. Continued approval may be contingent on those confirmatory trial results.

The COMPASS Trial: What to Watch

The Phase 2/3 COMPASS confirmatory trial is the most important ongoing study in this program. It randomizes patients 2:1 to receive either AVLAYAH or idursulfase (the current standard of care, Elaprase), with a planned 96-week treatment duration. The trial is global and includes both pediatric and young adult participants with Hunter syndrome.

COMPASS is designed to do what the Phase 1/2 study could not: compare AVLAYAH to standard of care in a randomized, controlled design and assess whether the biomarker normalization translates into measurable clinical benefit in terms of cognitive and neurological function. The primary clinical endpoints will need to capture developmental trajectories over time, which is methodologically challenging in a disease with considerable individual variability.

The trial results are expected to take several years to mature fully. During that time, AVLAYAH is available for clinical use under the accelerated approval, and prescribing decisions will be made on the basis of the current Phase 1/2 biomarker and secondary data.

What We Still Do Not Know

Long-term cognitive outcomes

Biomarker normalization is the most encouraging early signal possible in a disease where the brain has historically been unreachable. Whether it translates into meaningfully preserved or improved cognitive trajectories over years will be answered by COMPASS. That answer will take time and will matter enormously for how this therapy is used and positioned.

Cost and access

Denali has not yet publicly announced U.S. list pricing. For ultra-rare disease therapies of this complexity, pricing will directly determine real-world access, especially for families navigating insurance coverage determinations or living outside the United States. The Rare Pediatric Disease Priority Review Voucher granted alongside the approval has significant commercial value for Denali and is a standard incentive mechanism created specifically to encourage development of therapies for conditions like Hunter syndrome, where market size alone does not support development investment. Denali Patient Services is available as a support resource; the practical details of coverage assistance will matter significantly for affected families.

Global regulatory submissions

COMPASS is designed to support global regulatory submissions beyond the U.S. Families outside the United States are watching those timelines closely.

Why This Matters Beyond Hunter Syndrome

The neuroscience community is watching this approval closely for reasons that extend beyond the MPS II patient population.

The blood-brain barrier has been one of the central unsolved problems in treating neurological diseases for decades. Most large molecules cannot get through it. Delivering enzyme replacement therapy, gene therapy vectors, antibody-based biologics, or any other large therapeutic molecule to the brain in meaningful concentrations has required either intrathecal delivery (spinal administration) or has simply not been possible at all for most candidates.

Denali’s TransportVehicle platform is now a clinically validated approach to crossing that barrier in humans, not just a promising hypothesis from animal models. The company has applied the same technology to other conditions, including Alzheimer’s disease-related programs targeting BACE1. This approval is the kind of proof-of-concept that tends to accelerate an entire field of drug development. If COMPASS confirms the clinical benefit and the platform continues to hold up in other applications, the implications extend well beyond lysosomal storage disorders to neurodegenerative disease more broadly.

For related coverage of other rare pediatric disease FDA approvals and the regulatory frameworks supporting them, see our posts on the first gene therapy for genetic deafness and what the Rare Pediatric Disease PRV means for rare disease development and the UX111 gene therapy BLA for Sanfilippo syndrome now under FDA review.

For Families and Clinicians

For patients with Hunter syndrome and their families, AVLAYAH represents the first treatment specifically designed to address the neurological aspect of the disease. The therapy is available in the United States under the accelerated approval. The label specifies initiation in presymptomatic or symptomatic patients prior to advanced neurologic impairment, which underscores the importance of early identification and newborn screening programs for MPS II.

Optimal management of Hunter syndrome is through a specialist in metabolic or lysosomal storage disorders, ideally at a center with MPS expertise. The National MPS Society provides disease information, family support, a physician directory, and real-time updates on treatment access and the AVLAYAH program. Project Alive focuses specifically on MPS II research and family support. The National Organization for Rare Disorders (NORD) maintains a clinical overview of MPS II with current treatment and research information.

Sources

FDA approval press announcement: FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome. FDA.gov. March 25, 2026.

Denali Therapeutics investor press release: Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II). GlobeNewswire. March 25, 2026.

Phase 1/2 trial primary publication: Phase 1/2 study of tividenofusp alfa in Hunter syndrome. New England Journal of Medicine. January 1, 2026.

Phase 1/2 trial registration: NCT02055118. ClinicalTrials.gov.

COMPASS trial search: COMPASS tividenofusp. ClinicalTrials.gov.

NeurologyLive clinical coverage: FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome. neurologylive.com. March 2026.

Child Neurology clinical commentary: FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome. child-neurology.org. March 2026.

PharmExec approval coverage: FDA Approves Avlayah for Treatment of Hunter Syndrome. pharmexec.com. 2026.

Elaprase (idursulfase) FDA approval: FDA approves idursulfase for Hunter syndrome. FDA.gov.

Blood-brain barrier overview: Blood-Brain Barrier. StatPearls. NCBI.

TfR1-mediated transcytosis: Transferrin Receptor as a Brain Drug Delivery Vehicle. PMC6558765.

MPS II/Hunter syndrome GARD: Mucopolysaccharidosis Type II. rarediseases.info.nih.gov.

IDS gene: IDS gene. NCBI.

Glycosaminoglycans biology: Glycosaminoglycans. StatPearls. NCBI.

Accelerated approval pathway: Accelerated Approval Program. FDA.gov.

Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

Denali TV platform: Blood-Brain Barrier Science. denalitherapeutics.com.

Patient resources: National MPS Society | Project Alive | NORD: MPS II | ClinicalTrials.gov: COMPASS

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. AVLAYAH received accelerated approval; continued approval may be contingent on confirmatory trial results from the COMPASS study. Treatment decisions for Hunter syndrome should be made in consultation with a qualified specialist in metabolic or lysosomal storage disorders.

Ovarian Cancer Has Resisted Almost Every Drug Thrown at It in the Platinum-Resistant Setting. Lifyorli™ Just Changed That by Targeting Cortisol.

April 6, 2026

📌 The essentials On March 25, 2026, the FDA approved Lifyorli (relacorilant, Corcept Therapeutics) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. This is a full approval based on overall survival data, not accelerated approval. The mechanism: relacorilant is an oral, selective glucocorticoid receptor (GR) antagonist. It blocks cortisol’s tumor-protective action that suppresses apoptosis in cancer cells, sensitizing them to nab-paclitaxel’s cytotoxic effect. Dosing: relacorilant 150 mg orally on the day before, day of, and day after each nab-paclitaxel infusion, given in 28-day cycles. The clinical basis: Phase 3 ROSELLA trial (NCT05257408), published in The Lancet, showing median overall survival of 16.0 versus 11.9 months (HR 0.65; p=0.0004), a 35% reduction in risk of death. The 18-month OS rate was 46% versus 27%. NCCN has designated relacorilant plus nab-paclitaxel as a preferred regimen for platinum-resistant ovarian cancer.

For roughly thirty years, the story of platinum-resistant ovarian cancer has been one of persistent failure. Trial after trial. Checkpoint inhibitor after checkpoint inhibitor. PARP inhibitor combinations. Antibody-drug conjugates. Antiangiogenics beyond bevacizumab. The disease has resisted almost everything, and the graveyard of Phase 3 trials that failed in this setting is long and dispiriting.

Platinum-resistant ovarian cancer is defined by a clinical reality: the cancer progresses within six months of completing platinum-based chemotherapy. At that point, the treatment options narrow sharply. Single-agent non-platinum chemotherapy, including pegylated liposomal doxorubicin, paclitaxel, gemcitabine, and topotecan, with or without bevacizumab, has been the mainstay. Response rates are modest. Survival is poor.

On March 25, 2026, the FDA approved Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is the first FDA-approved selective glucocorticoid receptor antagonist, a category of drug that does not target the tumor directly, but instead targets the role cortisol plays in helping tumors resist the chemotherapy meant to kill them. The pivotal ROSELLA trial, published simultaneously in The Lancet, delivered something this disease has not seen in a long time: a statistically robust overall survival improvement.

The Disease: Why Platinum-Resistant Ovarian Cancer Is So Hard to Treat

Ovarian cancer is the most lethal gynecologic malignancy. In 2024, an estimated 320,000 new cases were diagnosed globally and approximately 210,000 women died from the disease, accounting for about 4.8% of all cancer-related mortality. In the United States, ovarian cancer kills approximately 12,800 women annually. The high mortality relative to incidence reflects a disease that is typically diagnosed at advanced stage (III or IV), when cure is unlikely.

Platinum-based chemotherapy, carboplatin and cisplatin, has been the backbone of ovarian cancer treatment for three decades. Most patients initially respond well. The problem is recurrence: approximately 70% of patients with advanced ovarian cancer will relapse, and through successive platinum cycles, resistance becomes inevitable. Once a patient’s cancer progresses within six months of the last platinum regimen, they are classified as platinum-resistant, and the therapeutic landscape changes dramatically for the worse.

Why this setting has been so difficult: the failed trials The list of Phase 3 trials that failed to improve overall survival in platinum-resistant ovarian cancer is extensive. Checkpoint inhibitors have largely disappointed in ovarian cancer despite transforming outcomes in melanoma, lung cancer, and other solid tumors. The ARTISTRY-7 trial, evaluating nemvaleukin plus pembrolizumab versus chemotherapy, was negative. The underlying biology is partially explanatory: ovarian tumors often have immunosuppressive microenvironments with low T-cell infiltration, limited PD-L1 expression, and mechanisms that actively exclude immune cells. Notably, the ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab plus paclitaxel plus or minus bevacizumab in platinum-resistant ovarian cancer did ultimately produce the first significant PFS and OS benefit with immunotherapy in this setting. That approval, covered here on Health Evidence Digest, required PD-L1 CPS of 1 or higher for the indicated population. For patients who do not meet that biomarker threshold or who have progressed after immunotherapy, the unmet need remained enormous. What was needed for that broader population was a different angle of attack entirely.

The Mechanism: Cortisol as a Shield for Tumor Cells

The biological rationale for relacorilant starts with a question that oncologists have long observed but had limited tools to address: why does chemotherapy work initially in ovarian cancer, then stop working? Part of the answer involves the tumor microenvironment, and specifically the role cortisol plays within it.

Cortisol is a glucocorticoid hormone produced by the adrenal glands that regulates stress responses, inflammation, and immune function. In normal physiology, cortisol plays many important and beneficial roles. In tumor biology, however, cortisol, acting through the glucocorticoid receptor (GR) expressed in many cancer cell types, contributes to chemotherapy resistance through a specific and well-characterized mechanism: it inhibits apoptosis.

Apoptosis is programmed cell death, the cellular self-destruct mechanism that chemotherapy is specifically designed to trigger. Taxane chemotherapies like nab-paclitaxel work by disrupting microtubule function during cell division, causing mitotic arrest and ultimately apoptotic cell death. When cortisol activates GR signaling in tumor cells, it suppresses the apoptotic machinery, effectively giving those cells a cortisol-mediated shield against the chemotherapy that should be killing them.

Relacorilant is an oral, selective glucocorticoid receptor antagonist. It competes with cortisol at the GR binding site, blocking the receptor without activating it. With GR signaling suppressed, cortisol’s protection of tumor cells from apoptosis is reduced, and the tumor cells become more sensitive to nab-paclitaxel’s intended mechanism. Relacorilant is selective: it binds only to the glucocorticoid receptor, not to the progesterone, androgen, mineralocorticoid, or estrogen receptors. This selectivity is what distinguishes it from older, non-selective glucocorticoid antagonists like mifepristone.

The dosing schedule and why it matters for tolerability Relacorilant is taken orally at 150 mg on three specific days per 28-day cycle: the day before each nab-paclitaxel infusion, the day of the infusion, and the day after. Nab-paclitaxel is administered intravenously on days 1, 8, and 15 of each cycle. This intermittent dosing design is intentional. Continuous glucocorticoid receptor blockade would interfere with the body’s normal cortisol-dependent functions, including immune regulation, glucose metabolism, and stress response. By limiting GR blockade to the three days surrounding each chemotherapy infusion, the regimen specifically targets the period when cortisol’s tumor-protective effects are most relevant, while minimizing disruption to normal physiology. This design choice is supported by the trial’s safety data: no cases of adrenal insufficiency were reported in the ROSELLA trial.

The ROSELLA Trial: Design and Full Results

The Phase 3 ROSELLA trial (NCT05257408) was an international, randomized, controlled, open-label study conducted across 117 sites in 14 countries, including the United States, multiple European nations, South Korea, Brazil, Argentina, Canada, and Australia, in collaboration with the GOG Foundation, ENGOT, APGOT, LACOG, and ANZGOG. Enrollment ran from January 2023 to April 2024.

Patient population

Eligible patients were adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, defined as disease progression within six months of the last platinum-based therapy. All had received one to three prior systemic therapy regimens, and all had prior bevacizumab exposure. Patients requiring chronic corticosteroids were excluded. The median patient age was 61 to 62 years.

Randomization and treatment

381 patients were randomized 1:1 to relacorilant 150 mg plus nab-paclitaxel 80 mg/m² (n=188), or nab-paclitaxel alone at 100 mg/m² (n=193). The monotherapy arm received a higher dose of nab-paclitaxel to reflect the absence of a chemo-sensitizing partner. The dual primary endpoints were progression-free survival (PFS) by RECIST 1.1 and blinded independent central review, and overall survival.

Results

Endpoint	Relacorilant plus nab-paclitaxel	Nab-paclitaxel alone
Median overall survival	16.0 months (95% CI 13.0 to 18.3)	11.9 months (95% CI 10.0 to 13.8)
OS hazard ratio	0.65 (95% CI 0.51 to 0.83)	Reference
OS p-value	0.0004	—
Reduction in risk of death	35%	—
12-month OS rate	60%	50%
18-month OS rate	46%	27%
Median PFS (BICR)	6.5 months (95% CI 5.6 to 7.4)	5.5 months (95% CI 3.9 to 5.9)
PFS hazard ratio	0.70 (95% CI 0.54 to 0.91)	Reference
PFS p-value	0.0076	—
Reduction in risk of progression	30%	—
12-month PFS rate	25%	13%
Second PFS (PFS2) hazard ratio	0.73 (p=0.0037)	Reference

Source: Olawaiye AB et al. The Lancet. 2026. doi:10.1016/S0140-6736(26)00462-9. ROSELLA trial (NCT05257408).

The OS data maturity at the final analysis was 76%, meaning three-quarters of patients had experienced the endpoint, making this a robust and interpretable dataset. The Lancet publication notes that the Kaplan-Meier survival curves show progressively widening separation over time, suggesting durable benefit rather than early separation that converges. The 18-month OS rate difference — 46% versus 27% — is particularly striking: at 18 months, nearly half of patients on the combination were still alive, compared with just over one-quarter on chemotherapy alone.

The benefit was consistent across all prespecified subgroups, including patients who had received two versus three prior lines of therapy, those with prior PARP inhibitor exposure, and across geographic regions. No biomarker selection was required for eligibility or benefit, which means the improvement applies to the broad platinum-resistant ovarian cancer population, not a molecularly defined subset.

The principal investigator of the ROSELLA trial, Dr. Alexander B. Olawaiye, MD, Director of Gynecologic Cancer Research at Magee-Womens Hospital of UPMC, characterized the finding at the SGO Late-Breaker presentation as the first demonstration that modulating the steroid receptor pathway, specifically the glucocorticoid receptor, can produce benefit in the treatment of platinum-resistant ovarian cancer, noting that the uniqueness of the pathway makes this new in every way.

Safety: What the Data Shows

The combination arm had a higher rate of grade 3 or higher treatment-emergent adverse events than the monotherapy arm: 74.5% versus 59.5%. The primary driver was hematologic toxicity, particularly neutropenia (44% versus 25% in the combination arm) and anemia (18% versus 9%). These findings reflect the addition of any chemotherapy-sensitizing agent and are consistent with what clinicians encounter in other combination regimens.

Adverse event (20% or higher incidence)	Combination arm	Monotherapy arm
Decreased hemoglobin	Most common, all grades	Lower rate
Neutropenia (grade 3 or higher)	44%	25%
Fatigue	20% or higher	Present
Nausea	20% or higher	Present
Diarrhea	20% or higher	Present
Decreased platelets	20% or higher	Present
Rash	20% or higher	Present
Decreased appetite	20% or higher	Present
Anemia (grade 3 or higher)	18%	9%
Adrenal insufficiency	0 cases	0 cases
Deaths attributed to relacorilant	0	0

Two specific safety findings deserve emphasis. First, no cases of adrenal insufficiency were observed, validating the intermittent dosing design. Second, peripheral neuropathy, a known concern with taxane chemotherapy, occurred at similar rates in both arms, suggesting relacorilant did not worsen this chemotherapy-related toxicity.

The prescribing label carries a contraindication for patients who require corticosteroids for a life-saving indication, because GR blockade would impair their effectiveness. Patients on systemic corticosteroids for severe asthma, inflammatory bowel disease, or immunosuppression following transplant require careful evaluation before initiating Lifyorli. Prescribing information warnings include neutropenia and severe infection risk, adrenal insufficiency monitoring, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.

What This Approval Represents

The NCCN Clinical Practice Guidelines in Oncology added Lifyorli plus nab-paclitaxel as a preferred regimen for platinum-resistant ovarian cancer following the approval. That designation reflects the committee’s assessment that the overall survival data from ROSELLA represents a meaningful advance for a patient population with very limited meaningful advances over the past decade.

Three aspects of the ROSELLA data deserve specific emphasis as markers of robustness. The OS analysis is mature: 76% data maturity is high for an ongoing survival analysis and ensures the hazard ratio estimate is reliable. Subsequent therapies were balanced between the two arms, ruling out the possibility that post-progression treatment differences explain the survival benefit. And the benefit was consistent across all predefined subgroups, including those heavily pretreated and those with prior PARP inhibitor exposure.

What we do not yet know: open questions for clinical practice No biomarker predicted response. ROSELLA enrolled without biomarker selection and found benefit across all subgroups. That is good news for broad access, but it means there is not yet a way to identify which patients are most likely to respond, or whether some patients have particularly high GR expression that drives greater benefit. Corcept and academic collaborators are likely studying this as a post-approval research question. Patient-reported quality of life. The ROSELLA trial included EORTC quality-of-life measures as secondary endpoints. Full patient-reported outcome analysis had not been comprehensively presented at time of writing. For patients in this setting, tolerability and quality of remaining life matter alongside survival data. Relacorilant in other tumor types. Corcept has active or planned trials of relacorilant in platinum-sensitive ovarian cancer, endometrial cancer, cervical cancer, pancreatic cancer, and prostate cancer. The proof-of-concept from ROSELLA that GR antagonism can sensitize tumors to chemotherapy may accelerate these programs.

Regulatory Status and Access

FDA approval

Approved March 25, 2026, for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. This is a full approval, based on overall survival data from ROSELLA meeting both co-primary endpoints.

European Medicines Agency

Corcept has submitted a Marketing Authorisation Application (MAA) to the EMA for relacorilant in platinum-resistant ovarian cancer. Relacorilant has received orphan drug designation from the European Commission for ovarian cancer treatment. The EMA review is ongoing.

Patient support

Corcept has established Lifyorli Support for patients and healthcare providers at 1-855-439-6754 (1-85-LIFYORLI). For questions about eligibility, prior authorization support, or financial assistance programs, this is the recommended first contact.

For patients and families navigating platinum-resistant ovarian cancer, the Ovarian Cancer Research Alliance and the Foundation for Women’s Cancer both maintain updated treatment information, clinical trial directories, and peer support resources. For related HED coverage of ovarian cancer treatment advances in 2026, see our post on pembrolizumab becoming the first approved immunotherapy for platinum-resistant ovarian cancer and our analysis of vepdegestrant and the PROTAC mechanism in breast cancer as examples of how novel mechanisms of action are reshaping gynecologic and breast oncology in the same period.

Sources

FDA approval: FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA.gov. March 25, 2026.

Corcept press release (approval): FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist. ir.corcept.com. March 25, 2026.

Corcept press release (SGO/OS data): Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet. ir.corcept.com. April 10, 2026.

Primary OS publication: Olawaiye AB et al. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. The Lancet. 2026. doi:10.1016/S0140-6736(26)00462-9

PFS publication: Lorusso D et al. ROSELLA: a phase 3 study of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. The Lancet. 2025;405:2205-2216.

ROSELLA trial registration: NCT05257408. ClinicalTrials.gov.

CancerNetwork OS coverage: Relacorilant/Nab-Paclitaxel Reduces Risk of Death by 35% in Platinum-Resistant Ovarian Cancer. cancernetwork.com. April 2026.

CURE coverage: Lifyorli Combo Approved in Platinum-Resistant Ovarian Cancer. curetoday.com. March 2026.

Targeted Oncology: Relacorilant Demonstrates Significant OS in Platinum-Resistant Ovarian Cancer. targetedonc.com. April 2026.

PROC treatment landscape: Current Treatments, Future Strategies for Platinum-Resistant Ovarian Cancer. AJMC. March 2026.

PROC unmet need review: Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance. PubMed. 2023. PMID:37079311.

NCCN guidelines: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. NCCN.

Glucocorticoid receptor biology: Glucocorticoid Receptor Signaling in Cancer. PMC7694440.

Apoptosis reference: Apoptosis. StatPearls. NCBI.

Cortisol overview: Cortisol. StatPearls. NCBI.

RECIST/PFS methodology: New Response Evaluation Criteria in Solid Tumours. PMC3107543.

Checkpoint inhibitors in ovarian cancer: Immune Checkpoint Inhibitors in Ovarian Cancer. PMC7174922.

PARP inhibitors: PARP Inhibitors. cancer.gov.

Neutropenia: Neutropenia. StatPearls. NCBI.

Patient resources: Ovarian Cancer Research Alliance | Foundation for Women’s Cancer | NCCN Ovarian Cancer Guidelines | Lifyorli Support: 1-855-439-6754

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for platinum-resistant ovarian cancer should be made in consultation with a qualified gynecologic oncologist.

GLP-1 Drugs and Suicidal Thoughts: The FDA Reviewed 107,910 Patients and 2.2 Million Real-World Users. What It’s Now Asking Drug Makers to Remove.

April 5, 2026

📌 Where This Review Stands as of January 2026: Read This First January 13, 2026: The FDA issued an updated Drug Safety Communication concluding that its comprehensive review, spanning 91 clinical trials, 107,910 patients, and a real-world cohort of 2.24 million users, found no evidence of increased suicidal behavior or ideation with GLP-1 receptor agonists. The FDA has formally requested removal of suicidality warnings from the prescribing information for semaglutide, tirzepatide, and liraglutide. This is the FDA’s clearest signal that it considers the concern resolved. The European Medicines Agency reached a similar conclusion in April 2024 after its own independent review. Important nuance: the FDA’s update also examined anxiety, depression, irritability, and psychosis, and found no increased risk for these psychiatric adverse events either. Patients should not stop GLP-1 medications without consulting their healthcare provider. If you are experiencing mood changes or distressing thoughts, contact your clinician and call or text 988.

When a drug is used by tens of millions of people, any signal in the adverse event database draws attention, even when that signal does not establish causation. That is the story of how GLP-1 receptor agonists and suicidality became a major pharmacovigilance question, why it took more than two years and two regulatory agencies to work through the evidence, and why the answer that emerged from one of the largest drug safety analyses ever conducted matters for patients and clinicians navigating this question.

The conclusion: the FDA reviewed the evidence systematically and comprehensively. It found no causal link. It is now asking manufacturers to remove the suicidality warning language. Getting to that conclusion required understanding why the signal appeared, why it was worth investigating seriously, and why the initial reports did not mean what some feared.

How the Signal Emerged and Why It Was Worth Investigating

GLP-1 receptor agonists, the class that includes semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and others, have become among the most widely prescribed drugs in modern medicine. More than 40 million Americans have taken semaglutide alone. At that scale, rare adverse events generate measurable counts in pharmacovigilance databases even when those events occur at the same rate as in untreated patients.

The concern originated in Europe. In 2023, the European Medicines Agency received reports of suicidal thoughts and self-injury in patients taking semaglutide and liraglutide. The EMA initiated a formal safety review. The FDA, which had already added precautionary language to certain GLP-1 labels, also began a systematic evaluation. In January 2024, the FDA announced preliminary findings with no evidence of a causal link, but stated the review was not yet complete. The January 13, 2026 Drug Safety Communication represents the completed review.

Why the initial signal was plausible enough to investigate seriously Several biological mechanisms made a GLP-1/suicidality connection worth examining. GLP-1 receptors are expressed not just in the pancreas and gut but throughout the brain, including in regions involved in mood regulation, reward processing, and appetite. Semaglutide is known to reduce what is sometimes described as “food noise,” the intrusive, preoccupying thoughts about food. Whether this appetite-suppressing CNS effect could, in some patients, contribute to a broader hedonic blunting or mood change was a reasonable hypothesis to test. Additionally, rapid weight loss from any cause is associated with increased risk of mood disruption, nutritional deficiency, and in some cases a paradoxical worsening of psychological wellbeing when results do not match expectations. Patients who begin GLP-1 therapy with unrealistic expectations and experience slower-than-expected weight loss may be particularly vulnerable. An umbrella review published in Healthcare (MDPI) in 2025 specifically identified unrealistic treatment expectations as a factor associated with suicidal ideation in GLP-1 users, independently of any pharmacological mechanism. The precedent from lorcaserin (Belviq), a weight-loss drug withdrawn in 2020 due to cancer risk that had also carried a suicidality warning, created additional regulatory pressure to examine this class carefully. And context matters: obesity and type 2 diabetes both independently elevate the baseline risk of depression and suicidality, meaning any population study in GLP-1 users is working against a backdrop of elevated baseline risk.

What the FDA’s Review Actually Examined

The January 2026 Drug Safety Communication represents one of the most comprehensive pharmacovigilance analyses ever conducted for a drug class. The FDA’s review incorporated three distinct streams of evidence.

1. FAERS adverse event report review

The FDA conducted detailed reviews of suicidal thoughts and action reports in its Adverse Event Reporting System (FAERS) database. It found that the reports were limited in detail and that suicidal events could be explained by other factors, including the underlying conditions for which GLP-1s are prescribed. A peer-reviewed FAERS analysis by McIntyre et al. (2024), applying Bradford Hill criteria for causality assessment, found disproportionate reporting of suicidal ideation with semaglutide and liraglutide, but no disproportionate reporting of actual suicidal behavior, suicide attempts, or completed suicide for any GLP-1. Their conclusion: no causal link exists when confounders are considered.

2. Meta-analysis of 91 clinical trials (107,910 patients)

The FDA conducted a meta-analysis pooling data from 91 placebo-controlled clinical trials of GLP-1 medications: 60,338 patients treated with GLP-1s and 47,572 treated with placebo. This is among the largest drug safety meta-analyses ever assembled for a single question. The results did not demonstrate an increased risk of suicidal behavior or ideation with GLP-1s. The analysis also examined related psychiatric outcomes, including anxiety, depression, irritability, and psychosis, and found no increased risk for any of these either.

3. Sentinel System real-world cohort study (2.24 million users)

The FDA’s Sentinel System, a large database of health insurance claims and patient health records, was used to conduct a retrospective cohort study comparing the risk of intentional self-harm between new users of GLP-1 receptor agonists and new users of SGLT2 inhibitors. The study included 1,161,983 GLP-1 users and 1,081,155 SGLT2 users. This real-world analysis found no increased risk of intentional self-harm with GLP-1 use.

Evidence stream	Scale	Finding
FAERS adverse event review	Detailed case-by-case review	No clear causal relationship; limited report detail; events explainable by underlying conditions
Clinical trial meta-analysis	91 trials, 107,910 patients (60,338 GLP-1 vs 47,572 placebo)	No increased risk of suicidal ideation, behavior, anxiety, depression, irritability, or psychosis
Sentinel real-world cohort	2,243,138 users (1.16M GLP-1 vs 1.08M SGLT2 inhibitor)	No increased risk of intentional self-harm with GLP-1 use
EMA independent review (April 2024)	EU-based pharmacovigilance and clinical trial data	Evidence insufficient to support causal association; no label change warranted

Beyond the FDA: What Independent Research Shows

The regulatory conclusions are consistent with the direction of the independent peer-reviewed literature, which has grown substantially since 2023.

The Nature Medicine study (semaglutide vs. comparators, n=240,618)

A study published in Nature Medicine, led by researchers at Case Western Reserve University and the National Institute on Drug Abuse, used electronic health records from 240,618 patients with overweight or obesity prescribed semaglutide or a non-GLP-1 medication for weight management. Semaglutide was associated with a lower risk of incident suicidal ideation (HR 0.27) and recurrent suicidal ideation (HR 0.44) compared with other agents. Dr. Nora Volkow, MD, Director of the National Institute on Drug Abuse (NIDA), was explicit about the appropriate interpretation of this finding in the publication’s commentary: the study does not indicate that taking semaglutide could reduce the risk of suicidal ideation or that it actively protects against suicidal ideation, as such a conclusion would require clinical trials.

Mendelian randomization: no genetic link

A Mendelian randomization study by Nguyen (2024) used genetic variants associated with GLP-1 pathway activity as proxies for long-term drug-like exposure. This approach can detect causal biological effects independent of confounders. The study found no causal evidence linking the glycemic and BMI-lowering effects of GLP-1 receptor agonists to an increased risk of suicide attempts, either in the general population or in individuals with pre-existing mental health conditions.

Systematic reviews and meta-analyses

A 2025 systematic review in Diabetes/Metabolism Research and Reviews (Bushi et al.) pooled observational cohort and case-control studies. It found no consistent association between GLP-1 use and increased suicidal ideation or behavior in the general diabetes or obesity population. An umbrella review published in Healthcare (MDPI) in 2025 synthesized 12 reviews and meta-analyses and found results consistent across studies, with no significant association between GLP-1 use and suicidality. A meta-analysis of 31 RCTs involving approximately 85,000 patients found no significant difference in psychiatric disorders (OR 0.97; 95% CI 0.83 to 1.15) or suicidal behavior (OR 0.86) between GLP-1 and placebo arms.

The Critical Confounding Issue: Obesity and Diabetes Independently Elevate Suicide Risk

This point deserves its own section because it is the single most important piece of context for interpreting any report connecting GLP-1 drugs to suicidality.

Obesity is independently associated with elevated rates of depression, anxiety, and suicidal ideation. Type 2 diabetes is independently associated with the same. People prescribed GLP-1 receptor agonists are, by definition, drawn from a population with higher baseline risk of psychiatric adverse events than the general population. When a drug is given to millions of people from a higher-risk population, adverse events including suicidal ideation will be reported, even if the drug itself plays no causal role.

This is called confounding by indication: the condition being treated (obesity, diabetes) is itself a risk factor for the outcome being studied (suicidal ideation). Properly controlled studies, using comparator groups of patients with the same underlying conditions on different medications, or using the Mendelian randomization approach to remove confounders entirely, consistently fail to find excess suicidal risk attributable to GLP-1 drugs.

The co-prescription signal: a nuance worth knowing One finding from the Bushi et al. systematic review warrants specific clinical attention: patients co-prescribed antidepressants showed a substantially higher reporting odds ratio for suicidal ideation (ROR 4.45; 95% CI 2.52 to 7.86), and those co-prescribed benzodiazepines showed a similarly elevated signal (ROR 4.07; 95% CI 1.69 to 9.82). This suggests that individuals with pre-existing mental health conditions who are also taking GLP-1 drugs may warrant closer psychiatric monitoring. This does not mean GLP-1 drugs caused the suicidality in these patients. It almost certainly reflects the fact that patients already on antidepressants or benzodiazepines have higher baseline psychiatric vulnerability. But it is a reasonable clinical signal: if a patient is already being treated for depression or anxiety and starts a GLP-1, maintaining existing mental health follow-up is sensible practice regardless of the FDA’s label change.

What the FDA Is Asking Drug Makers to Remove and What Stays

The January 2026 Drug Safety Communication is explicit: the FDA is requesting removal of suicidal behavior and ideation warnings from the prescribing information for semaglutide, tirzepatide, and liraglutide. This is a formal regulatory request to manufacturers, not a unilateral FDA label change. Manufacturers submit the proposed language and the FDA approves it. The practical effect is the same.

What stays in the label: the established, class-wide safety profile for GLP-1s including gastrointestinal effects, thyroid C-cell tumor risk for injectable GLP-1s, pancreatitis risk, and the contraindications relevant to each specific drug. None of these are affected by the suicidality review.

The FDA also emphasized that despite requesting label removal, clinicians should continue to be prepared to discuss the findings with patients and to refer individuals who report suicidal ideation or behavior to mental health professionals, not because the drug is causing it, but because the population taking these drugs has higher baseline psychiatric risk that warrants clinical awareness.

For Patients: What This Means in Practice

Do not stop your GLP-1 medication based on the suicidality concern. The evidence does not support a causal link. Stopping abruptly without medical guidance can worsen blood sugar control or cause rebound weight gain. Read our post on what happens when semaglutide is discontinued for more context on managing GLP-1 therapy transitions.

Do tell your prescribing clinician about any changes in mood, new or worsening depression, or distressing thoughts. This applies to any medication in any patient and is not specific to GLP-1s, but it is always important to keep your care team informed.

If you already have a history of depression or anxiety, ensure your mental health provider is aware you are starting a GLP-1. Not because of a drug risk, but because any significant metabolic change, body image shift, or treatment expectation mismatch can affect mental health in people already managing psychiatric conditions.

If you are having thoughts of self-harm or suicide, call or text 988 (U.S. Suicide and Crisis Lifeline) any time, or go to your nearest emergency department. Do not wait for a scheduled appointment.

The label change does not mean GLP-1 drugs are risk-free. They have well-documented side effects including gastrointestinal effects, injection site reactions, and for some patients, hair loss. The specific concern about suicidality, however, has been investigated extensively and not confirmed.

For Clinicians: Practical Takeaways

The FDA’s label change request does not eliminate the clinical rationale for psychiatric monitoring in GLP-1 users. The population prescribed these drugs has elevated baseline psychiatric risk, and the co-prescription signal (antidepressants, benzodiazepines) warrants awareness even if it likely reflects underlying vulnerability rather than a drug effect.

Discuss realistic treatment expectations before initiating GLP-1 therapy. The umbrella review found that unrealistic expectations and disappointment with weight loss results were associated with elevated suicidal risk signals. Setting evidence-based expectations, specifically that 10 to 15% weight loss is typical and results vary, is now both good clinical practice and supported by the safety literature.

The review’s psychiatric adverse event finding is broader than suicidality. No increased risk of anxiety, depression, irritability, or psychosis was found across 91 trials. This is useful context for reassuring patients who ask about neuropsychiatric effects broadly.

For patients with a history of suicidality or active psychiatric illness who are candidates for GLP-1 therapy, consider co-management with their mental health provider, not because of drug risk but because of the baseline complexity.

For related HED coverage of GLP-1 medications and their evolving indications, see our posts on GLP-1 medications and PCOS fertility research in 2026, the approval of Wegovy HD (semaglutide 7.2 mg) and the STEP UP trial data, and the FDA’s post-marketing study requirements for Foundayo (orforglipron).

If you or someone you know is struggling with mental health right now, please reach out to the 988 Suicide and Crisis Lifeline by calling or texting 988, available 24 hours a day, 7 days a week in the U.S.

Sources

FDA Drug Safety Communication (Jan 2026): Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking Certain Type 2 Diabetes and Obesity Medicines. January 13, 2026. fda.gov.

Pharmacy Times coverage: FDA Finds No Increased Suicide Risk With GLP-1 Medications, Requests Removal of Warning Labels. pharmacytimes.com. 2026.

EMA review conclusion: European Medicines Agency. Assessment report on GLP-1 receptor agonists and risk of suicidal behavior and ideation. April 2024.

McIntyre et al. FAERS analysis: McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH. Association between GLP-1 RAs and suicidality using Bradford Hill criteria. Expert Opin Drug Saf. 2024;23(1):47-55. doi:10.1080/14740338.2023.2295397

Nature Medicine cohort: Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024. doi:10.1038/s41591-023-02750-1

Bushi et al. systematic review: Bushi G et al. Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis. Diabetes Metab Res Rev. 2025. doi:10.1002/dmrr.70037

Umbrella review: Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence. Healthcare (MDPI). 2025;13(22):2958. doi:10.3390/healthcare13222958

ScienceDirect systematic review: The effect of GLP-1 receptor agonists on measures of suicidality: A systematic review. ScienceDirect. 2025. doi:10.1016/j.jad.2025.01.007

Lancet eClinical case-time-control: Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study. EClinicalMedicine. 2024. doi:10.1016/j.eclinm.2024.102983

Mendelian randomization: Nguyen et al. Causal assessment of GLP-1 RA effects and suicide attempts via Mendelian randomization. 2024.

FDA Sentinel System: FDA’s Sentinel Initiative. fda.gov/safety/fdas-sentinel-initiative.

Bradford Hill criteria reference: Bradford Hill Criteria. PMC4589481.

GLP-1 receptor agonist overview: GLP-1 Receptor Agonists. StatPearls. NCBI.

SGLT2 inhibitor overview: SGLT2 Inhibitors. StatPearls. NCBI.

Crisis resources: 988 Suicide and Crisis Lifeline. 988lifeline.org. Call or text 988, available 24/7.

Disclaimer: Health Evidence Digest provides general information about drug safety research for educational purposes. This content is not a substitute for professional medical advice. If you are experiencing thoughts of self-harm or suicide, contact 988 or seek emergency care immediately. Do not stop prescribed medications without consulting your healthcare provider.

The KRESLADI Trial Data That Just Earned the First Gene Therapy Approval for LAD-I

April 5, 2026

📌 The essentials On March 26, 2026, the FDA approved KRESLADI (marnetegragene autotemcel, Rocket Pharmaceuticals), the first gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I), indicated specifically for pediatric patients who lack an available HLA-matched sibling donor. The clinical basis: a Phase 1/2 trial (NCT03812263) enrolling 9 children with molecularly confirmed severe LAD-I, showing 100% HSCT-free survival at one year (95% CI 66 to 100; p less than 0.001), 0 graft failures, and sustained neutrophil CD18 expression through median 4.2-year follow-up. Results published in the New England Journal of Medicine. This is an accelerated approval based on biomarker surrogates (CD18 and CD11a expression). Confirmatory post-marketing studies are required. Rare Pediatric Disease Priority Review Voucher granted alongside approval. The boxed warning: lentiviral vector-mediated insertional oncogenesis, requiring long-term post-treatment monitoring.

Most children born with severe Leukocyte Adhesion Deficiency Type I do not survive to their second birthday without treatment. Their white blood cells, the immune system’s first responders, lack a critical surface protein called CD18 that allows them to exit the bloodstream and reach the site of infection. Without it, bacteria and fungi go virtually unchallenged. The infections are relentless, poorly responsive to antibiotics, and frequently fatal. Omphalitis, infection of the umbilical stump, is sometimes the first sign, in a newborn just days old.

The only curative option before March 2026 was an allogeneic hematopoietic stem cell transplant from an HLA-matched sibling donor. Most children do not have one. Transplants from mismatched donors carry substantial risks: graft failure, graft-versus-host disease, and transplant-related mortality. Some families faced a situation with no good path forward.

On March 26, 2026, the FDA approved KRESLADI (marnetegragene autotemcel), the first gene therapy for severe LAD-I, indicated specifically for pediatric patients without an available matched sibling donor. The clinical trial behind it enrolled nine children. None had graft failure. All survived. The youngest were infants; all who were enrolled under age one were alive beyond age two. The data was published in the New England Journal of Medicine.

Leukocyte Adhesion Deficiency Type I: What It Is and Why It Kills

LAD-I is caused by biallelic (two-copy) loss-of-function mutations in the ITGB2 gene, which encodes CD18, the beta-2 integrin subunit that pairs with CD11 proteins to form integrin complexes on the surface of leukocytes. These CD11/CD18 complexes, particularly LFA-1, composed of CD11a and CD18, are what allow white blood cells to adhere to the inner walls of blood vessels and migrate through them into infected tissues. Without functional CD18, neutrophils and other leukocytes stay in circulation. They cannot reach wounds. They cannot engulf bacteria at infection sites. Infections that a healthy immune system would clear in days become life-threatening emergencies.

Severe LAD-I is defined by CD18 surface expression below 2% of normal. At this level, even minor infections, a skin abrasion, a gum infection, the umbilical cord stump, can become life-threatening. The infection burden is compounded by delayed wound healing: without leukocyte migration, the inflammatory cascade needed for tissue repair does not function properly.

How rare is LAD-I? The incidence of LAD-I in the U.S. is estimated at approximately 1 in 100,000 to 1 in 200,000 live births. Roughly two-thirds of affected patients have the severe form. Based on approximately 3.6 million U.S. births per year, that translates to roughly 12 to 24 new cases of severe LAD-I annually in the United States. Global prevalence is higher in regions where consanguineous marriage is more common, as LAD-I is autosomal recessive, meaning a child must inherit one mutated ITGB2 copy from each parent. In some Middle Eastern and South Asian populations, the disease burden is proportionally higher. The ultra-rarity of the disease is part of why gene therapy development has been slow: a clinical trial enrolling 9 patients represents a meaningful fraction of the total global patient population who meet enrollment criteria at any given time.

How KRESLADI Works: Lentiviral Gene Correction of the Patient’s Own Stem Cells

KRESLADI is an autologous gene therapy, meaning it is manufactured from the patient’s own cells, corrected in the laboratory, and returned to the same patient. This eliminates the core risk of donor-based transplantation: immune mismatch. There is no foreign tissue to reject, and no graft to mount an attack against the host.

The manufacturing process follows a sequence of steps before the patient receives a single intravenous infusion:

Mobilization and apheresis: The patient receives drugs (G-CSF and/or plerixafor) to mobilize hematopoietic stem cells (HSCs) from the bone marrow into the bloodstream. These CD34+ progenitor cells are then collected by apheresis, a process that filters blood through a machine and harvests stem cells.

Ex vivo gene correction: The harvested CD34+ cells are taken to a manufacturing facility and transduced with a lentiviral vector carrying a functional copy of the ITGB2 gene. The lentiviral vector integrates into the cell genome, providing a permanent genetic correction. A back-up collection of unmodified CD34+ cells is preserved in case engraftment fails.

Myeloablative conditioning: Before infusion, the patient undergoes full myeloablative conditioning, high-dose chemotherapy designed to eliminate the existing defective bone marrow and create space for the corrected cells to engraft. This is a significant clinical intervention and the primary source of short-term treatment-related risk.

Infusion: The gene-corrected cells are infused intravenously in a single dose. They travel to the bone marrow, engraft, and begin producing CD18-expressing neutrophils and other leukocytes, ideally for the patient’s lifetime.

Lentiviral vectors and insertional oncogenesis: the long-term risk to understand A lentiviral vector works by integrating a copy of the therapeutic gene into the patient’s genome, which is what makes the correction permanent. But integration is not perfectly targeted: the vector can insert near oncogenes (cancer-promoting genes), potentially disrupting their regulation. This risk is called insertional oncogenesis. Early-generation retroviral gene therapies for X-linked SCID caused leukemia in some patients, creating lasting concern about the category. Modern lentiviral vectors like the one used in KRESLADI are self-inactivating (SIN): the viral promoter that could drive oncogene expression is deleted after integration, substantially reducing this risk. The prescribing information for KRESLADI includes a formal warning for lentiviral vector-mediated insertional oncogenesis and requires long-term follow-up monitoring. No cases of insertional oncogenesis were observed in the Phase 1/2 trial, but with a median follow-up of 4.2 years in only 9 patients, long-term surveillance remains a post-marketing requirement. This is not a reason to avoid the therapy in a disease with near-certain early mortality without treatment, but it is a reason for enrolled families to maintain follow-up.

The Phase 1/2 Clinical Trial: Nine Patients, Published in NEJM

The trial supporting KRESLADI’s approval (NCT03812263) was an open-label, single-arm, multicenter Phase 1/2 study conducted at leading pediatric immunodeficiency centers including UCLA and Great Ormond Street Hospital in London. It enrolled 9 children with molecularly confirmed severe LAD-I (biallelic ITGB2 mutations, CD18 expression below 2% of normal) who lacked an available HLA-matched sibling donor.

The primary endpoints were biomarker-based: neutrophil CD18 and CD11a surface expression at 12 and 24 months, used as surrogates for restored immune function. Secondary endpoints included safety, engraftment, infection events, and HSCT-free survival. Results were published in the New England Journal of Medicine.

Outcome	Result
Study population	9 children with severe LAD-I, biallelic ITGB2 mutations, no HLA-matched sibling donor
HSCT-free survival at 1 year	100% (95% CI 66 to 100; p less than 0.001)
Graft failures	0 of 9
Median follow-up	4.2 years (range 3.6 to 5.7)
Neutrophil CD18 expression (Month 12)	Sustained increase in all 9 patients
Neutrophil CD18 expression (Month 42)	Sustained in all 7 patients with available data
Neutrophil CD11a expression (Month 12)	Median 45% (range 18 to 75)
Neutrophil CD11a expression (Month 24)	Median 39% (range 17 to 65)
Patients enrolled below age 1 year	All alive beyond 2 years of age
Treatment-related serious adverse events	None reported
Insertional oncogenesis cases	None observed (ongoing monitoring required)

Source: Phase 1/2 clinical trial results for marnetegragene autotemcel in LAD-I. New England Journal of Medicine. NCT03812263.

The 100% HSCT-free survival figure warrants careful interpretation alongside the confidence interval (66 to 100%). With only 9 patients, the lower bound of that confidence interval means the true survival rate could theoretically be as low as 66%, which is not a negligible uncertainty. The FDA’s accelerated approval based on biomarker data rather than confirmed long-term clinical outcomes reflects this: the agency considered the surrogate endpoints (CD18 and CD11a expression) sufficiently likely to predict clinical benefit given the biological coherence and the disease’s natural history, while requiring confirmatory data through post-marketing studies.

What the 4.2-year median follow-up confirms is durability of the biomarker response: all 7 patients with data available at month 42 maintained sustained neutrophil CD18 expression. The correction appears stable across the observation period, which is among the longest available for any lentiviral hematopoietic gene therapy in a primary immunodeficiency.

Vinay Prasad, MD, MPH, Chief Medical and Scientific Officer and Director of the FDA Center for Biologics Evaluation and Research, stated at the time of approval that today’s accelerated approval provides a breakthrough treatment for pediatric patients with severe LAD-I, the first FDA-approved gene therapy to treat this disease.

KRESLADI vs. Allogeneic HSCT: Understanding the Comparison

The most meaningful clinical comparison for KRESLADI is not placebo. In a disease with near-certain early mortality, a placebo-controlled trial would be unethical. The relevant comparison is allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor, the only prior curative approach.

Feature	KRESLADI (gene therapy)	Matched sibling HSCT
Donor required	No, uses patient’s own cells	Yes, HLA-matched sibling
Availability	All eligible patients without matched sibling	Approximately 25 to 30% of patients have matched sibling
GVHD risk	None (autologous)	Significant, especially with mismatched donors
Graft failure risk	0 of 9 in trial	Higher with mismatched; lower with matched sibling
Conditioning required	Yes, full myeloablative	Yes, myeloablative or reduced-intensity
Insertional oncogenesis risk	Small but real (lentiviral vector)	None
Long-term follow-up data	Median 4.2 years (n=9)	Decades; large registry data available
Regulatory status	FDA accelerated approval (March 2026)	Standard curative approach (first-line when donor available)

The comparison highlights that KRESLADI is approved specifically for the gap population, those without an available HLA-matched sibling donor. It does not replace matched-sibling HSCT, which remains the standard approach when a donor is available. For families without that option, gene therapy now provides a curative path that did not previously exist.

The ongoing clinical evolution of HSCT is also worth noting. Haploidentical transplantation, using a partially matched donor such as a parent, is increasingly feasible through improved graft manipulation techniques and is being evaluated as an alternative for patients without matched siblings. The availability of KRESLADI creates an additional option alongside these evolving transplant approaches, giving clinicians and families more to consider.

Safety: What to Know Before Treatment

No treatment-related serious adverse events were reported in the Phase 1/2 trial, a notable finding given the severity of the conditioning regimen required. Most adverse reactions reflected the expected effects of myeloablative conditioning rather than the gene therapy product itself.

Common adverse reactions in the trial population included: mucositis, upper respiratory tract infection, viral infection, febrile neutropenia, skin lesions, nausea and vomiting, rash, pyrexia, device-related infection, decreased blood counts (hemoglobin, platelets, neutrophils, leukocytes), and elevated liver enzymes (AST, ALT).

The prescribing information includes formal warnings and precautions for:

Serious infections: susceptibility increases during the myeloablative conditioning period before engraftment is established
Veno-occlusive disease (hepatic VOD): monitor liver function tests during the first month following infusion
Neutrophil engraftment failure: defined as failure to achieve absolute neutrophil count of 500 cells per microliter or higher by Day 43; back-up unmodified CD34+ cells are preserved in case rescue is needed
Delayed platelet engraftment
Lentiviral vector-mediated insertional oncogenesis: long-term monitoring required
Hypersensitivity reactions

What Treatment Involves: The Full Patient Journey

For families whose child has been diagnosed with severe LAD-I and lacks an HLA-matched sibling donor, the path to KRESLADI involves a structured sequence of steps that requires specialized care at a qualified treatment center.

Genetic confirmation first

KRESLADI is indicated specifically for patients with severe LAD-I due to biallelic variants in ITGB2 confirmed by molecular testing, with CD18 expression below 2% of normal. Clinical diagnosis alone is not sufficient for eligibility. Genetic testing confirming the ITGB2 mutations is required.

Specialized treatment center

KRESLADI will be administered only at qualified treatment centers with experience in bone marrow transplantation and gene therapy. The manufacturing process, including mobilization, apheresis, ex vivo gene correction, and back-up cell preservation, requires institutional infrastructure that is not available at all pediatric centers. Rocket Pharmaceuticals indicated it plans a measured rollout to ensure quality and safety at launch.

Timing matters

The trial enrolled children as young as infants. Outcomes in LAD-I gene therapy, as in most gene therapies for primary immunodeficiencies, are generally better when treatment is given before significant infection-related damage has accumulated. Families who receive a diagnosis of severe LAD-I should contact a specialized immunodeficiency center promptly to discuss evaluation and next steps, rather than waiting for a clinical crisis.

Regulatory designations

KRESLADI received multiple FDA designations supporting its development:

With approval, Rocket Pharmaceuticals received a Rare Pediatric Disease Priority Review Voucher, a transferable regulatory instrument that entitles the holder to priority (6-month) FDA review for a future NDA or BLA. PRVs have historically traded in the $100 to $150 million range. Rocket may use the voucher for a future program or sell it; either way, it represents a financial mechanism designed to incentivize rare pediatric drug development.

For families whose child has been diagnosed with severe LAD-I or who are under evaluation for a primary immunodeficiency presenting with recurrent severe infections in infancy, the most important first step is early referral to a center with expertise in primary immunodeficiencies and gene therapy. The Immune Deficiency Foundation maintains a directory of immunodeficiency specialists and can connect families with clinical expertise. For questions about KRESLADI specifically, Rocket Pharmaceuticals’ medical affairs team and information on the treatment program are available through their website. The confirmatory post-marketing studies will build the long-term evidence base that the Phase 1/2 trial, while remarkable, cannot yet provide. Families who enroll in long-term follow-up contribute directly to that body of evidence.

Sources

FDA press release: FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I. FDA.gov. March 26, 2026.

Rocket Pharmaceuticals press release: Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe LAD-I. March 27, 2026. ir.rocketpharma.com.

FDA approval letter: BLA 125806/0 Approval Letter. March 26, 2026.

KRESLADI prescribing information: KRESLADI (marnetegragene autotemcel) Prescribing Information. Rocket Pharmaceuticals; 2026.

NEJM primary publication: Phase 1/2 clinical trial results for marnetegragene autotemcel in LAD-I. New England Journal of Medicine. NCT03812263.

Phase 1/2 trial registration: NCT03812263. Gene Therapy for Leukocyte Adhesion Deficiency Type I. ClinicalTrials.gov.

Pharmacy Times coverage: FDA Approves Marne-Cel, First Stem Cell-Based Gene Therapy for Pediatric Patients With LAD-I. pharmacytimes.com. March 2026.

Rheumatology Advisor: Gene Therapy Kresladi Approved for Severe Leukocyte Adhesion Deficiency-I. rheumatologyadvisor.com. March 2026.

BioPharm International: FDA Approval of Kresladi Expands Gene Therapy in Pediatric Rare Diseases. biopharminternational.com. April 2026.

Disease overview: Novoa EA et al. Leukocyte adhesion deficiency-I: A comprehensive review. J Allergy Clin Immunol Pract. 2018.

LAD-I GARD overview: Leukocyte Adhesion Deficiency Type 1. rarediseases.info.nih.gov.

CD18 biology: CD18 integrin biology. PMC5555401.

Lentiviral vectors: Lentiviral vectors in gene therapy. PMC6563422.

Insertional oncogenesis: Insertional oncogenesis risk in gene therapy. PMC8709598.

Hematopoietic stem cells: Hematopoietic Stem Cells. StatPearls. NCBI.

Myeloablative conditioning: Myeloablative Conditioning. StatPearls. NCBI.

Haploidentical HSCT: Haploidentical Transplantation. PMC7138706.

HLA matching in HSCT: HLA Matching in HSCT. StatPearls. NCBI.

Accelerated approval pathway: Accelerated Approval Program. FDA.gov.

Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

Patient resources: Immune Deficiency Foundation | NORD: LAD-I | Rocket Pharmaceuticals | ClinicalTrials.gov: LAD-I

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Treatment decisions for severe LAD-I should be made in consultation with a board-certified pediatric immunologist or hematologist at a center with expertise in gene therapy and primary immunodeficiencies. KRESLADI received accelerated approval; continued approval may be contingent on confirmatory post-marketing study results.

Prolia Costs $2,500 a Dose. There Are Now 19 Biosimilar Competitors. Here’s What That Means for Patients.

April 4, 2026

📌 The essentials On March 30, 2026, Teva Pharmaceutical received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia (denosumab, Amgen) for all five of Prolia’s approved indications. Commercial launch expected Q3 2026. This is the 19th FDA-approved denosumab biosimilar, not the first. Several have already launched commercially in the United States with modest savings of approximately 5 to 15% below Prolia’s list price. Critical distinction for patients: PONLIMSI is approved as a biosimilar but does NOT have interchangeable designation. Only Jubbonti (Sandoz) has interchangeable status for Prolia, meaning only Jubbonti can be substituted by a pharmacist without calling your prescriber. Simultaneously, Teva announced that the FDA and EMA have both accepted regulatory filings for its proposed omalizumab (Xolair) biosimilar. This is not an approval; it is the start of review. A Prolia discontinuation warning: do not stop denosumab abruptly for any reason, including a transition to a biosimilar. Rebound vertebral fractures are a documented serious risk. Any transition must be clinician-guided.

Osteoporosis affects an estimated 200 million people globally and is responsible for approximately 9 million fractures per year worldwide. In the United States, about 10 million adults have osteoporosis and another 44 million have low bone density, putting them at elevated fracture risk. Hip fractures in older adults carry a one-year mortality rate of up to 36%, a statistic that makes bone health a genuine life-or-death clinical priority, not a cosmetic concern.

Denosumab (Prolia, Amgen) is one of the most effective medications available for high-risk osteoporosis. It reduces vertebral fracture risk by up to 68%, hip fractures by 40%, and nonvertebral fractures by 20% in clinical trials. It is also, without insurance, a $2,506 injection administered twice a year, making it inaccessible or unaffordable for many of the patients who need it most.

On March 30, 2026, Teva Pharmaceutical received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia, and simultaneously announced that regulatory agencies in both the U.S. and Europe have accepted filings for its proposed biosimilar to Xolair (omalizumab), a biologic used in severe asthma, nasal polyps, and IgE-mediated food allergy. These are meaningful regulatory events, but they exist in a context that the original announcement does not capture: the denosumab biosimilar market is now crowded, savings to patients have been disappointingly modest so far, and understanding the difference between a biosimilar and an interchangeable biosimilar has real implications for whether your pharmacist can make the switch without calling your doctor.

What Denosumab Does and Why It Is So Expensive

Denosumab is a fully human monoclonal antibody that works by inhibiting RANKL, receptor activator of nuclear factor kappa-B ligand, a protein essential for the formation, function, and survival of osteoclasts, the cells responsible for breaking down bone. By blocking RANKL, denosumab suppresses bone resorption, which allows bone mineral density to increase and fracture risk to fall.

Amgen markets denosumab under two brand names: Prolia (60 mg subcutaneous injection every 6 months) for osteoporosis and bone loss from hormonal cancer therapies, and Xgeva (120 mg every 4 weeks) for preventing skeletal-related events in patients with bone metastases and giant cell tumors. The two products use the same molecule but are approved for different indications at different doses.

The $2,500+ price per dose reflects the cost of biologic drug manufacturing. Denosumab is produced in living cells using complex, expensive processes, not synthesized chemically like a small molecule tablet. Amgen has generated approximately $2.9 billion annually from Prolia alone. Despite recent patent expirations in the U.S. and Europe opening the door to biosimilar competition, the denosumab market has yet to see the dramatic price reductions that biosimilar proponents hoped for.

A critical clinical nuance: the rebound fracture risk on discontinuation Denosumab has a well-documented risk of rebound vertebral fractures when treatment is stopped abruptly. Because denosumab’s anti-resorptive effect reverses quickly after the drug clears the system, faster than bisphosphonates which accumulate in bone tissue, stopping denosumab without transitioning to another therapy can produce a rapid spike in bone turnover that significantly increases fracture risk in the first 12 to 24 months after discontinuation. Multiple cases of simultaneous vertebral fractures following denosumab discontinuation have been reported in the literature. Current guidelines recommend that patients stopping denosumab for any reason, including switching to a biosimilar if the transition is not managed carefully, receive bridging therapy with a bisphosphonate. This is not a biosimilar-specific concern, but it is relevant for any patient or prescriber navigating a formulary switch or change in product.

PONLIMSI: What the Approval Is Based On

PONLIMSI (denosumab-adet) received FDA approval on March 30, 2026, based on a totality of evidence demonstrating comparable efficacy, safety, and immunogenicity to Prolia. This evidence includes data from a randomized, double-blind Phase 3 clinical trial (NCT04729621) enrolling 332 women with postmenopausal osteoporosis, comparing denosumab-adet directly against Prolia across these endpoints.

PONLIMSI is approved for all five indications of the reference product Prolia:

Indication	Patient Population
Postmenopausal osteoporosis	Women at high risk for fracture, including history of fracture or multiple risk factors; or failed or intolerant to other osteoporosis therapy
Male osteoporosis	Men at high risk for fracture
Glucocorticoid-induced osteoporosis	Men and women on long-term corticosteroid therapy at high risk for fracture
Prostate cancer bone loss	Men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
Breast cancer bone loss	Women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

The EMA granted marketing authorization for PONLIMSI in Europe in November 2025, meaning the drug had already been approved in the EU before its U.S. clearance. Teva has indicated a commercial launch in the United States is expected in Q3 2026.

The Critical Distinction: Biosimilar vs. Interchangeable and Why It Matters for Patients

This is the most practically important piece of information in this post, and it was absent from the original coverage of PONLIMSI’s approval.

In the United States, there are two categories of FDA-approved biosimilars: biosimilar and interchangeable biosimilar. The difference matters at the pharmacy counter.

	Biosimilar	Interchangeable Biosimilar
FDA standard	Highly similar to reference product; no clinically meaningful differences in safety, purity, potency	Same as biosimilar PLUS: can be substituted without the prescriber’s involvement
Pharmacy substitution	Cannot be substituted automatically; requires prescriber authorization or new prescription in most states	Can be substituted by pharmacist without calling the prescriber (subject to state pharmacy laws)
Benefit to payer and patient	May require step therapy or prior authorization to access lower cost	Formulary substitution can happen more easily, driving faster cost competition
PONLIMSI status	Biosimilar only, NOT interchangeable (as of approval)	Jubbonti (Sandoz) has interchangeable designation
Real-world implication	Prescriber or insurer action typically needed	Pharmacist can swap without a call to the prescriber

Teva’s announcement did not mention an interchangeability designation for PONLIMSI. This means that in most U.S. states, a pharmacist cannot automatically substitute PONLIMSI for Prolia based on a prescription for denosumab. A clinician or insurer action is typically required. Patients who want to access the biosimilar version may need to ask their provider to write a new prescription specifically for PONLIMSI, or navigate a formulary preference process through their insurer.

The Denosumab Biosimilar Landscape: 19 Approvals, Modest Savings

PONLIMSI is not entering an empty market. By the time it launches in Q3 2026, it will be one of at least 19 FDA-approved denosumab biosimilars. Eighteen were approved by the end of December 2025, with PONLIMSI the first addition in 2026. Several have already launched commercially in the United States.

Biosimilar	Company	FDA Status	Notes
Jubbonti / Wyost	Sandoz	Approved March 2024; launched June 2025	First to market; interchangeable designation; 14.5% below Prolia WAC
Osenvelt / Stoboclo	Celltrion	Launched July 2025	5 to 10% discount range reported
Jubereq / Osvyrti	Accord BioPharma	Launched October 2025	Competitive pricing
Enoby / Xtrenbo	Gedeon Richter / Hikma	Approved; not yet launched	—
Bilprevda / Bildyos	Henlius / Organon	Approved; not yet launched	—
PONLIMSI	Teva	Approved March 2026; Q3 2026 launch expected	No interchangeability designation announced

The savings picture has been a disappointment relative to earlier expectations. Sandoz’s Jubbonti, the first approved interchangeable denosumab biosimilar, launched in June 2025 at a list price approximately 14.5% below Prolia’s wholesale acquisition cost. Celltrion’s biosimilars entered at an estimated 5 to 10% discount. A published budget impact model in the Journal of Medical Economics projected savings of $0.59 per member per month for health plans at medium conversion rates over five years, meaningful at scale, but not the 50 to 80% price reductions that biosimilar competition drove in markets like Europe.

Why are U.S. denosumab biosimilar savings so modest compared to Europe? In the UK, biosimilar adoption within the first year of launch routinely exceeds 90% of market share, driven by NHS tender-based procurement and institutional formulary switches. British rheumatologist Dr. Muhammad Nisar noted to Medscape that clinicians feel very comfortable with denosumab biosimilars, with great belief in their efficacy and safety. In the U.S., the market structure is fundamentally different. Amgen has kept Prolia competitively priced through rebates to pharmacy benefit managers (PBMs) and insurers. The net price paid by many payers may already be below the biosimilar list price after rebates. This perverse dynamic, in which originator rebates can make a brand-name drug cheaper to a payer than the biosimilar list price, is a structural feature of the U.S. drug market that dampens biosimilar adoption and competition. The interchangeability designation matters here too. Only Sandoz’s Jubbonti has interchangeable status for Prolia, allowing direct pharmacy substitution. The other approved denosumab biosimilars, including PONLIMSI, require prescriber action or payer-directed formulary changes to reach patients, slowing the pace of market conversion.

The Xolair Biosimilar Filing: A Different Market, A Different Opportunity

Teva’s simultaneous announcement that both the FDA and EMA have accepted filings for its proposed biosimilar to Xolair (omalizumab, Genentech/Novartis) is a separate and strategically distinct event from the PONLIMSI approval.

What omalizumab is and who uses it

Omalizumab (Xolair) is a monoclonal antibody that works by binding to free IgE, immunoglobulin E, the antibody class central to allergic responses, and blocking its interaction with IgE receptors on mast cells and basophils. By reducing free IgE levels, omalizumab prevents the downstream allergic cascade that produces symptoms in atopic disease.

Xolair is approved in the U.S. for: moderate-to-severe persistent allergic asthma inadequately controlled by inhaled corticosteroids in patients 6 and older whose asthma is related to a perennial allergen; chronic rhinosinusitis with nasal polyps in adults; chronic spontaneous urticaria in patients whose symptoms are inadequately controlled by antihistamines; and IgE-mediated food allergies in patients 1 year and older. That food allergy indication, the most recent addition, significantly expanded the patient population that might use omalizumab.

The market context

Global omalizumab sales are estimated at $3.5 to $3.7 billion annually, making this a commercially meaningful biosimilar target. Regulatory filing acceptance by both FDA and EMA simultaneously means Teva’s submission was complete enough for substantive review. This is not an approval; it is the beginning of the regulatory review process. The FDA’s standard review clock for biosimilar applications is 12 months from acceptance.

The omalizumab biosimilar market is at an earlier stage than denosumab. The omalizumab biosimilar landscape will be watched carefully by allergists, pulmonologists, and patients with severe allergic disease who currently pay thousands of dollars per year for brand-name Xolair, a cost that is a meaningful access barrier for many.

What This Means in Practice: Guidance for Patients

If you are currently on Prolia or another denosumab product

Do not stop denosumab without a medical plan for what comes next. The rebound fracture risk on discontinuation is real and serious. Any transition to a biosimilar should be clinician-guided, maintaining the same dosing schedule (every 6 months for Prolia indications) and likely incorporating a bisphosphonate bridge if you stop denosumab for any reason.

If cost is a barrier to accessing denosumab, ask your prescriber or pharmacist specifically about available biosimilar options. If your insurer’s formulary includes an interchangeable denosumab biosimilar like Jubbonti, your pharmacist may be able to substitute automatically. For non-interchangeable biosimilars like PONLIMSI, a prescriber action is required. Medicare Part B, through which administered biologics are often covered, has specific biosimilar substitution rules worth understanding with your provider.

If you are on Xolair for allergic asthma, nasal polyps, urticaria, or food allergy

A biosimilar is not yet available. Teva’s application is under review, and even after approval, launch timing will depend on regulatory processes and commercial decisions. Continue your current treatment as prescribed. Monitor your insurer’s formulary for updates in 2026 and 2027.

The Gap Between Biosimilar Approval and Patient Savings

The denosumab biosimilar story is instructive for understanding how U.S. drug pricing actually works and why regulatory approval of a biosimilar does not automatically translate to patient savings.

When Prolia’s key patents began expiring, the expectation was that biosimilar competition would drive meaningful price reductions, as it has in Europe. Instead, 19 FDA approvals later, the most aggressive biosimilar discount achieved is about 14.5% below Prolia’s list price. The originator still commands most of the market. The structural reasons are complex: Amgen’s rebate practices, the lack of interchangeability designation for most competitors, the physician-administered nature of the injection (which keeps it under Part B rather than Part D, with different substitution rules), and the clinical hesitancy around switching patients who have been stable on a therapy that must not be interrupted without a plan.

Flanigan et al. noted in their 2025 Journal of Medical Economics budget impact analysis that even a small discount of 5% for a biosimilar referencing Xgeva and Prolia could represent millions of dollars in savings for a health plan, with the potential for reinvestment to further expand access. Those savings are real at scale even when they feel modest at the individual patient level.

None of this means biosimilar approvals like PONLIMSI are without value. For payers, even modest per-dose discounts multiply across large patient populations. For patients in countries with less fragmented pricing structures, competitive biosimilar availability is genuinely transformative. And building a competitive biosimilar market, however slowly, creates the foundation for the price competition that patients deserve.

The omalizumab filing, if it leads to approval and launch, enters a somewhat less saturated biosimilar market. The recent addition of the food allergy indication has expanded the potential patient population substantially. That approval, if and when it comes, may be a more commercially differentiated moment than PONLIMSI in the already crowded denosumab space.

For related coverage of how access and affordability are shaping the drug landscape in 2026, see our post on FDA approval of the first generic dapagliflozin, where a similar story of high list prices, biosimilar or generic entry, and the gap between approval and real-world savings is unfolding in the type 2 diabetes space.

Sources

Teva press release: Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair (omalizumab). March 30, 2026. ir.tevapharm.com.

Clinical Advisor coverage: FDA Approves Teva’s Prolia Biosimilar Ponlimsi, Accepts Xolair Biosimilar for Review. clinicaladvisor.com. April 2026.

Drug Topics: FDA Approves Denosumab-Adet as Biosimilar to Prolia. drugtopics.com. March 2026.

Center for Biosimilars: FDA Approves Teva Biosimilar for Denosumab in Osteoporosis. centerforbiosimilars.com. March 2026.

GaBI Online: FDA approves denosumab biosimilar Ponlimsi. gabionline.net. April 2026.

Medscape: Two More Denosumab Biosimilars Approved in the US. medscape.com. October 2025.

Managed Healthcare Executive: Biosimilar denosumab could save $0.59 per member per month. managedhealthcareexecutive.com. February 2026.

Journal of Medical Economics budget impact: Flanigan J, Chaplin S, et al. A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population. J Med Econ. 2025;28(1):2027-2038. doi:10.1080/13696998.2025.2027-2038.

PONLIMSI Phase 3 trial: NCT04729621. ClinicalTrials.gov.

GoodRx pricing: How Much Is Prolia Without Insurance? goodrx.com.

Rebound fracture risk: Rebound vertebral fractures after denosumab discontinuation. PMC6683162.

Denosumab mechanism: Denosumab. StatPearls. NCBI.

RANKL biology: RANKL in bone biology. PMC3386061.

Hip fracture mortality: Hip fracture 1-year mortality. PMC6530614.

FDA biosimilars explained: Biosimilar and Interchangeable Products. FDA.gov.

FDA approved biosimilar products: FDA-Approved Biosimilar Products. FDA.gov.

Prolia FDA approval: FDA approves denosumab for osteoporosis. FDA.gov.

Xgeva FDA approval: FDA approves denosumab (Xgeva). FDA.gov.

Xolair FDA approval: FDA approves omalizumab for allergic asthma. FDA.gov.

IgE biology: IgE in allergy. StatPearls. NCBI.

PBM market structure: Pharmacy Benefit Managers. PMC7748166.

Bisphosphonates: Bisphosphonates. StatPearls. NCBI.

Patient resources: Bone Health and Osteoporosis Foundation | FDA Biosimilar Products List | GoodRx Prolia pricing

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about denosumab therapy, including switching between reference products and biosimilars, should be made in consultation with a qualified prescriber familiar with the patient’s bone health history and fracture risk. Never discontinue denosumab without medical guidance.

Foundayo™ Is the First GLP-1 Pill You Can Take Any Time, With Anything. Here’s What the Trial Data Shows and What the FDA Is Still Waiting to Find Out.

April 4, 2026

📌 The essentials On April 1, 2026, the FDA approved Foundayo (orforglipron, Eli Lilly) for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related comorbidity, as an adjunct to diet and exercise. The approval came 50 days after NDA submission under the Commissioner’s National Priority Voucher (CNPV) program, the fastest approval of a new molecular entity since 2002. What makes it mechanistically distinctive: orforglipron is the first oral non-peptide small molecule GLP-1 receptor agonist approved for weight management, which means it can be taken once daily at any time, with or without food, with or without water restrictions. No injection. No fasting window. No 30-minute waiting window. ATTAIN-1 trial data: mean weight loss of 11.2% at 72 weeks (highest dose, 36 mg, efficacy estimand) versus 2.1% with placebo. Among patients who completed the full 72 weeks, mean weight loss was 12.4%. Self-pay pricing: $149 per month. For patients with established cardiovascular disease: oral semaglutide currently has an approved CV risk reduction indication that Foundayo does not yet have. The CV outcomes trial (ATTAIN-CVRD) is a mandated post-marketing study. Full coverage of all nine FDA post-marketing requirements: Foundayo Post-Marketing Studies Explained.

Forty-two percent of American adults have obesity. Effective GLP-1 receptor agonist therapies have been available since 2021. And yet fewer than 1 in 10 eligible adults are actually using them, a gap driven by needle anxiety, cost, shortage-related access barriers, and the logistical friction of injectable or restrictively-administered medications.

On April 1, 2026, the FDA approved Foundayo (orforglipron), the first GLP-1 receptor agonist for weight management that can be taken once daily at any time of day, with or without food, with or without water. No injection. No empty-stomach requirement. No 30-minute waiting window. That combination of properties is genuinely new in this drug class, and it matters most for the patients who do not currently use GLP-1 therapies despite qualifying for them.

This post covers what Foundayo is, what makes it mechanistically different, what the ATTAIN clinical trials showed across all doses, how it compares to oral semaglutide, what the safety profile looks like, and what the FDA is still requiring Lilly to study before the full picture is known.

Approved in 50 Days: The CNPV Program Behind the Speed

Foundayo was approved 50 days after NDA submission, making it the fastest new molecular entity approval since 2002 and the first new molecular entity cleared under the Commissioner’s National Priority Voucher (CNPV) program. The standard FDA NDA review clock is 10 months (Priority Review) or 12 months (Standard). The CNPV program, which designates certain applications as national health priorities, compresses that timeline dramatically.

Obesity, affecting 42% of U.S. adults and costing the healthcare system an estimated $173 billion annually, qualifies as a national priority. The speed of approval reflects both the strength of the clinical data and a regulatory policy decision that the public health benefit of broader access to effective obesity pharmacotherapy outweighs the risk of uncertainty about longer-term safety endpoints. Those uncertainties are being managed through a substantial set of post-marketing requirements, nine mandated studies, covered in depth in our companion post.

For full coverage of all nine post-marketing requirements including the cardiovascular outcomes trial, the 15-year thyroid cancer registry, the pediatric study, the pregnancy exposure registry, and what the suicidality and alopecia studies are examining, see: Foundayo Was Approved in 50 Days. Now the FDA Wants a Decade of Safety Follow-Up.

What Makes Foundayo Mechanistically Different From Other GLP-1 Drugs

Every GLP-1 receptor agonist currently available, including semaglutide, tirzepatide, liraglutide, and dulaglutide, is a peptide: a short chain of amino acids that mimics the naturally occurring GLP-1 hormone. Peptides are effective, but they are destroyed by stomach acid if swallowed, which is why most GLP-1 drugs are injected. Oral semaglutide (Rybelsus, Wegovy oral) gets around this using a chemical absorption enhancer called SNAC, but the workaround requires specific conditions: it must be taken with no more than 4 oz of plain water on an empty stomach, at least 30 minutes before eating or drinking anything else.

Orforglipron is not a peptide. It is a small molecule, a non-peptide synthetic compound small enough and chemically stable enough to survive the digestive tract and reach GLP-1 receptors without any of those constraints. No absorption enhancer needed. No fasting window. No specific water volume. No food timing restrictions. Once daily, any time, with anything.

Why the small-molecule distinction matters beyond convenience The peptide-vs-small-molecule difference has practical implications beyond the dosing schedule. Small molecules can typically be manufactured using conventional pharmaceutical chemistry at substantially lower per-unit cost than biologics produced in living cells. This manufacturing accessibility is one reason orforglipron is priced at $149 per month for self-pay patients, already lower than the list prices of injectable semaglutide and tirzepatide products. Small molecules also do not require refrigeration, which means no cold-chain logistics and no concerns about storing the drug in warm environments. For patients in rural or lower-income settings, or in countries without reliable cold-chain infrastructure, this is not a trivial advantage. The trade-off, as the clinical data shows, is that the weight loss achieved with orforglipron is somewhat lower than with the highest-dose injectable GLP-1s. How much that trade-off matters depends entirely on the patient and what they need from the treatment.

The ATTAIN Clinical Trial Program: All the Numbers

Foundayo’s approval was based primarily on data from the ATTAIN Phase 3 program. The pivotal ATTAIN-1 trial was published in the New England Journal of Medicine in November 2025.

ATTAIN-1: Adults without diabetes (n=3,127, 72 weeks)

Enrolled adults with obesity (BMI of 30 or higher) or overweight with at least one weight-related comorbidity, without type 2 diabetes. Randomized to orforglipron 6 mg, 12 mg, or 36 mg daily, or placebo.

Outcome at 72 weeks	Placebo	6 mg	12 mg	36 mg
Mean weight loss (efficacy estimand)	2.1%	7.5%	8.4%	11.2%
Mean weight loss (per protocol, completer)	0.9%	—	—	12.4%
Achieved 10% or more weight loss	—	30.9%	37.9%	54.6%
Achieved 15% or more weight loss	—	16.5%	21.7%	36.0%
Achieved 20% or more weight loss	—	7.3%	10.9%	18.4%
Discontinuation due to adverse events	—	5.3%	6.8%	10.3%

Source: Wharton S et al. NEJM. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774. ATTAIN-1 (NCT05869903).

The 11.2% mean weight loss at the highest dose, or 12.4% among those who completed the full 72 weeks of treatment, is meaningful but sits below what injectable semaglutide and tirzepatide achieve at their highest doses (approximately 15 to 17% and 20 to 22% respectively). Cardiometabolic markers improved significantly across all doses: waist circumference, systolic blood pressure, non-HDL cholesterol, and triglycerides all improved relative to placebo.

ATTAIN-MAINTAIN: Switching from injectables

Published December 2025, ATTAIN-MAINTAIN evaluated patients who had previously achieved weight loss on injectable Wegovy or Zepbound and then switched to oral orforglipron. The key finding: weight previously lost on injectables was maintained. Patients switching from Wegovy maintained with an average difference of 0.9 kg; those from Zepbound similarly. This positions Foundayo as a viable long-term maintenance option for patients who achieve initial weight loss on injectables and want to transition to a no-injection routine.

Foundayo vs. Oral Semaglutide: The Head-to-Head Picture

The obvious comparison for Foundayo is oral semaglutide (Wegovy oral), approved in December 2025, the only other oral GLP-1 therapy. The two drugs are chemically different in an important way, and weighing the data and administration differences clearly helps patients and prescribers make the right choice.

Feature	Foundayo (orforglipron)	Oral semaglutide (Wegovy oral)
Molecule type	Small molecule (non-peptide)	Peptide plus SNAC absorption enhancer
Food and water restriction	None, any time with or without food	Empty stomach, 4 oz or less water, wait 30 min before eating
Refrigeration	Not required	Not required
Highest-dose weight loss (non-diabetic obesity)	Approximately 11 to 12% (ATTAIN-1, 36 mg)	Approximately 15% at 25 mg (OASIS 1 trial)
Head-to-head in T2D (ACHIEVE-3)	Orforglipron superior on HbA1c and weight vs. 14 mg oral sema	No direct obesity head-to-head trial yet
CV outcomes indication	Not yet: ATTAIN-CVRD trial ongoing (post-marketing requirement)	Yes, based on SELECT trial
Self-pay price	$149 per month	Not yet available as standalone oral obesity prescription at time of writing
Key drug interaction	CYP3A4/P-gp inhibitor: simvastatin limit of 20 mg	Less significant CYP interactions

The cardiovascular outcomes gap is the most clinically significant difference for high-risk patients. Oral semaglutide carries an approved CV risk reduction indication (reducing major adverse cardiovascular events in overweight or obese adults with established CV disease), based on the SELECT trial. Foundayo does not currently have this indication. That data is pending from ATTAIN-CVRD, one of the nine mandated post-marketing studies. For patients with established cardiovascular disease choosing between these two oral GLP-1 options, that distinction matters.

Who Foundayo Is Approved For

Foundayo is approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:

Adults with a BMI of 30 kg/m² or higher (obesity), or
Adults with a BMI of 27 kg/m² or higher (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea

It is not approved for use in children, in pregnancy, or in combination with other GLP-1 receptor agonists. The diabetes indication is a separate regulatory pathway. Lilly has indicated plans to submit for a type 2 diabetes indication using ACHIEVE-4 trial data by end of Q2 2026.

How to Take Foundayo

Administration is straightforward by GLP-1 standards:

One tablet taken orally once daily, any time of day, with or without food or water
Tablets should be swallowed whole, not split, crushed, or chewed
If a dose is missed, take it as soon as possible on the same day. If the day has passed, skip the missed dose; never double up
No titration schedule is described in the currently approved prescribing information; discuss with your prescriber
No refrigeration required; standard room temperature storage

Safety: What You Need to Know Before Starting

Boxed warning: medullary thyroid carcinoma

Foundayo carries a boxed warning for the risk of medullary thyroid carcinoma (MTC). This warning is a class effect shared by all GLP-1 receptor agonists, based on rodent studies showing dose-dependent C-cell tumors. In humans, after many years of GLP-1 use in millions of patients, a clear MTC signal has not definitively emerged in post-marketing surveillance. The warning remains, and the FDA is requiring a 15-year thyroid cancer registry as a post-marketing study. Foundayo is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Serious risks

Pancreatitis: discontinue if pancreatitis is suspected; do not restart
Severe gastrointestinal reactions: severe nausea, vomiting, and diarrhea; may require hydration support
Acute kidney injury: may occur in the context of dehydration from GI adverse events
Hypoglycemia: particularly when co-administered with insulin or sulfonylureas; dose reduction of the concurrent medication may be needed
Gallbladder disease: cholelithiasis and cholecystitis reported with GLP-1 use
Serious hypersensitivity reactions: anaphylaxis and angioedema reported with the class

Common side effects

The most common adverse reactions, occurring in 5% or more of patients in ATTAIN-1, were gastrointestinal: nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain. These are consistent with the GLP-1 class effect and typically occur early in treatment and improve over time. Non-GI common side effects include headache, fatigue, and hair loss (alopecia). Hair loss has been reported with orforglipron as with other GLP-1s. The FDA is requiring a formal post-marketing characterization study to understand frequency, timing, severity, and reversibility.

The CYP3A4 drug interaction: do not overlook this

Orforglipron inhibits CYP3A4 and P-glycoprotein. The most clinically significant interaction: patients on simvastatin should not exceed 20 mg daily while taking Foundayo. This is not a listed side effect; it is a drug-drug interaction requiring dose adjustment of the concurrent medication. Clinicians and pharmacists should review the full prescribing information for all interactions before initiating.

Perioperative considerations

GLP-1 receptor agonists slow gastric emptying, which increases the risk of aspiration under general anesthesia. The American Society of Anesthesiologists recommends holding GLP-1 drugs before elective procedures requiring anesthesia or deep sedation. The FDA is requiring a dedicated delayed gastric emptying post-marketing study for orforglipron. In the interim, the class guidance applies: inform your anesthesiologist that you are taking a GLP-1 drug before any procedure.

Cost, Availability, and Access

Patient type	Price and access path
Commercially insured (eligible)	$25 per month via Lilly’s copay assistance program
Self-pay or uninsured	$149 per month through LillyDirect pharmacy
Medicare Part D (from July 1, 2026)	$50 per month via CMS Bridge Model, first major Medicare obesity drug coverage expansion
Medicaid	Coverage varies by state; contact insurer for formulary status
Initial availability	LillyDirect at launch; retail pharmacy and telehealth to follow

What the FDA Is Still Waiting to Learn

The 50-day approval speed comes with a genuine trade-off: several important safety and long-term efficacy questions remain open. The FDA has mandated nine post-marketing studies that Lilly is legally required to complete, covering cardiovascular outcomes, liver injury, delayed gastric emptying, a 15-year thyroid cancer registry, pediatric safety and efficacy in ages 6 to 12, pregnancy and lactation outcomes, suicidality assessment, alopecia characterization, and a 5-year pharmacoepidemiology study.

For coverage of all nine requirements and what each one means, see our companion post: Foundayo Was Approved in 50 Days. Now the FDA Wants a Decade of Safety Follow-Up.

For related HED coverage on GLP-1 medications, see our posts on GLP-1 medications and PCOS fertility research, the FDA’s review of GLP-1 medications and suicidality reports, and Wegovy HD (semaglutide 7.2 mg) and the STEP UP trial data.

Sources

FDA approval announcement: FDA Approves First New Molecular Entity Under National Priority Voucher Program. FDA.gov. April 1, 2026.

Lilly approval announcement: FDA Approves Lilly’s Foundayo (orforglipron). investor.lilly.com. April 1, 2026.

ATTAIN-1 primary publication: Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. NEJM. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774

ATTAIN-1 trial registration: NCT05869903. ClinicalTrials.gov.

ATTAIN-MAINTAIN: Lilly. Orforglipron helped people maintain weight loss after switching from injectables. December 18, 2025. investor.lilly.com.

ACHIEVE-3 head-to-head: Orforglipron vs. oral semaglutide head-to-head Phase 3. The Lancet. February 2026.

SELECT trial (oral semaglutide CV outcomes): Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM. 2023. doi:10.1056/NEJMoa2307563

FDA NDA approval letter: NDA 220934 Orig1s000 Approval Letter. April 14, 2026. accessdata.fda.gov.

Foundayo prescribing information: Foundayo (orforglipron) Prescribing Information. Eli Lilly. April 2026.

Oral GLP-1 comparison: Two Oral GLP-1s Increase Options for Patient Care. Medscape. April 2026.

Medicare CMS Bridge Model: CMS. CMS Bridge Model for obesity drug coverage. cms.gov.

GLP-1 gastric emptying: Delayed Gastric Emptying and GLP-1 Receptor Agonists. PMC10183139.

ASA perioperative guidance: American Society of Anesthesiologists GLP-1 guidance. asahq.org.

CYP3A4 reference: CYP3A4. StatPearls. NCBI.

GLP-1 mechanism: GLP-1 Receptor Agonists. StatPearls. NCBI.

Semaglutide pharmacology: Semaglutide. StatPearls. NCBI.

HED companion post: Foundayo Was Approved in 50 Days. Now the FDA Wants a Decade of Safety Follow-Up.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Drug pricing information reflects figures at time of publication and is subject to change. Always consult a qualified healthcare provider regarding medication decisions.

365 Injections a Year, or 52. Awiqli Is the First Once-Weekly Basal Insulin and the Science Behind It Is More Interesting Than the Dosing Schedule.

April 4, 2026

📌 The essentials On March 26, 2026, the FDA approved Awiqli (insulin icodec-abae, Novo Nordisk), the first and only once-weekly basal insulin in history, for adults with type 2 diabetes. 52 injections per year instead of 365. The clinical basis: four randomized, treat-to-target ONWARDS Phase 3 trials enrolling approximately 2,900 adults with T2D. Three of the four trials showed statistically superior HbA1c reduction with icodec versus daily basal insulin. The fourth met non-inferiority. A meta-analysis across five ONWARDS trials showed a mean incremental HbA1c benefit of 0.17% (95% CI 0.06 to 0.28; p=0.003). The mechanism: insulin icodec binds reversibly to albumin via fatty acid side chains, creating a circulating reservoir that releases active insulin continuously over approximately 8 days (half-life approximately 196 hours). Why the T1D indication is absent: an earlier FDA Complete Response Letter cited the higher hypoglycemia rate in ONWARDS 6 (the type 1 trial). The March 2026 approval covers type 2 diabetes only. Critical clinical consideration: icodec’s 196-hour half-life means dose adjustments take 3 to 4 weeks to reach new steady state. Titrate conservatively, no more frequently than every 1 to 2 weeks.

Basal insulin has been a cornerstone of type 2 diabetes management for decades. It works by providing a slow, steady background level of insulin that covers overnight glucose production by the liver and keeps blood sugar from rising between meals. For millions of people with type 2 diabetes who cannot achieve adequate glycemic control with oral medications alone, basal insulin is not optional. It is what keeps them safe.

But daily injections are a burden. Not a small one. A patient starting daily basal insulin at age 60 faces 365 injections per year for the rest of their life. Studies consistently show that fear of injection, injection fatigue, and the daily management burden contribute to insulin omission, dose skipping, and delayed treatment initiation, all of which translate into worse glycemic control and worse outcomes.

On March 26, 2026, the FDA approved Awiqli (insulin icodec-abae), the first once-weekly basal insulin in history, 52 injections a year instead of 365. The clinical data behind it spans five randomized trials and approximately 4,000 patients. It shows not just non-inferiority to daily basal insulin, but in several studies, superior HbA1c reduction. Understanding how that is possible, and what the trade-offs are, requires going inside the chemistry.

How Awiqli Actually Works: The Albumin-Binding Depot Mechanism

Existing basal insulins, glargine (Lantus, Toujeo, Basaglar) and degludec (Tresiba), achieve their extended duration through different mechanisms. Glargine precipitates at physiological pH, forming microcrystals that dissolve slowly. Degludec forms multi-hexameric chains that dissociate gradually from the injection site. Both produce half-lives of 12 to 25 hours, sufficient for once-daily dosing.

Insulin icodec takes a fundamentally different approach. The molecule is engineered with two fatty acid side chains that allow it to bind reversibly to albumin, the most abundant protein in blood plasma. When injected, icodec does not just sit at the injection site waiting to dissolve. It enters the bloodstream and binds to circulating albumin, which acts as a reservoir. Only a small fraction of icodec is free and active at any given time; the rest is temporarily sequestered in the albumin-bound depot. As free icodec is cleared by the body, more is released from albumin to replace it.

The result is a half-life of approximately 196 hours, about 8 days. This is long enough that a single injection provides stable, continuous insulin coverage for an entire week, with a flat pharmacodynamic profile that avoids the peak-and-trough pattern that can contribute to hypoglycemia with shorter-acting insulins.

Why the long half-life creates a specific clinical consideration The same pharmacokinetic property that enables once-weekly dosing also means that any dose adjustment takes longer to reach a new steady state. With daily insulin, a dose increase or decrease produces a measurable effect within 1 to 2 days. With icodec’s 196-hour half-life, it takes approximately 3 to 4 weeks to reach a new steady state after a dose change. This has a practical implication for titration: icodec should be titrated conservatively, with dose adjustments made no more frequently than every 1 to 2 weeks based on fasting blood glucose. Aggressive titration, adjusting every few days as some patients do with daily insulins, risks overshoot and delayed hypoglycemia. The prescribing information provides specific titration guidance that clinicians should review carefully. Similarly, if a patient is transitioning off icodec to another insulin, the insulin effect persists for several days after the last dose. Overlap with a new insulin must be carefully managed to avoid hypoglycemia during the transition period.

Why This Is a Resubmission and Why Type 1 Diabetes Is Not on the Label

The March 2026 approval is not the first time Awiqli went through FDA review. In July 2024, the FDA issued a Complete Response Letter citing two issues: concerns about the manufacturing process, and concerns about the safety of insulin icodec specifically in patients with type 1 diabetes.

The type 1 concern is worth understanding. ONWARDS 6, the Phase 3 trial evaluating insulin icodec in T1D, showed that icodec was non-inferior to degludec for HbA1c reduction. But in T1D patients, the rate of clinically significant or severe hypoglycemia was meaningfully higher in the icodec arm than in the degludec arm. The FDA’s advisory committee voted against approval for T1D, and the agency’s concerns were reflected in the CRL.

Novo Nordisk’s response was pragmatic: rather than try to address the T1D concerns in the resubmission, which would have required additional clinical data and further delayed approval, the company resubmitted in September 2025 for the T2D indication only, where the efficacy and safety data were consistently robust. That resubmission was approved in March 2026.

Novo Nordisk has stated that it remains committed to exploring icodec for type 1 diabetes and plans to conduct a new clinical trial in this population. The T1D indication is not closed; it is deferred. For now, Awiqli is approved for adults with type 2 diabetes only.

The ONWARDS Trials: What the Clinical Evidence Shows

The FDA approval is based on four trials from the ONWARDS Phase 3a clinical program, all randomized, active-controlled, and treat-to-target in design. “Treat-to-target” means that insulin doses in both arms were titrated to achieve the same blood sugar goals, a rigorous design that tests whether the drugs perform equivalently under optimized conditions.

Trial	Population	Comparator	HbA1c reduction (icodec)	HbA1c reduction (comparator)
ONWARDS 1 (78 wk, n=984)	Insulin-naive T2D on non-insulin agents	Glargine U100 (once daily)	−1.55%	−1.35%*
ONWARDS 2 (26 wk, n=526)	T2D switching from daily basal insulin	Degludec (once daily)	−0.93%	−0.71%†
ONWARDS 3 (26 wk, n=588)	Insulin-naive T2D on non-insulin agents	Degludec (once daily)	−1.57%	−1.36%†
ONWARDS 4 (26 wk, n=582)	T2D on basal-bolus regimen	Glargine U100 (once daily)	−1.16%	−1.18% (NI met)

* Superior (p less than 0.001) vs. glargine U100. † Superior (p less than 0.003 to p less than 0.0007) vs. degludec. NI = non-inferiority. Source: Published ONWARDS trials in NEJM, Lancet, JAMA, Lancet Diabetes Endocrinology.

Three of the four trials showed statistically superior HbA1c reduction with icodec compared to daily basal insulin. The fourth (ONWARDS 4, in patients already on basal-bolus regimens) met the pre-specified non-inferiority margin. A meta-analysis across all five ONWARDS trials showed a mean incremental HbA1c benefit of 0.17% (95% CI 0.06 to 0.28; p=0.003) and an odds ratio of 1.51 (95% CI 1.14 to 1.99) for achieving HbA1c below 7% with icodec versus comparators.

ONWARDS 1 also demonstrated a secondary endpoint of superior Time in Range (blood glucose 70 to 180 mg/dL) with icodec compared to glargine U100, a clinically meaningful finding given the growing emphasis on TIR as an outcome measure alongside HbA1c. Additionally, in ONWARDS 1 and 3, a higher proportion of insulin-naive patients achieved an HbA1c target below 7% without clinically significant or severe hypoglycemia with icodec versus comparators, suggesting that the once-weekly drug can deliver better glycemic control without proportionally increasing hypoglycemia burden in this population.

Dr. Julio Rosenstock, MD, Clinical Professor at UT Southwestern Medical Center and Principal Investigator of the ONWARDS trial program, characterized the approval at the time of the FDA decision as underscoring the need for new alternative insulin options that may help patients work with their healthcare providers to determine what treatment works best for them.

The Hypoglycemia Picture: Nuanced, Not Alarming

Hypoglycemia is the most important safety consideration in any insulin therapy, and the icodec data requires careful interpretation rather than a headline summary.

In insulin-naive patients (ONWARDS 1 and 3), the picture is favorable: despite achieving better HbA1c control, icodec did not generate significantly more hypoglycemia than comparators, and more patients reached target HbA1c without experiencing level 2 or level 3 hypoglycemia.

The nuance comes in the switching studies (ONWARDS 2 and 3 for patients already on insulin). Here, numerically higher rates of clinically significant (level 2) or severe (level 3) hypoglycemia were observed with icodec compared to degludec. In ONWARDS 3, rates were 0.31 versus 0.15 events per patient-year. This difference reflects a specific pharmacokinetic challenge: when patients switch from daily to weekly insulin, there is an initial period during which the full icodec depot is being established. The prescribing information recommends initiating icodec at 20% higher than the previous total daily dose for patients switching from daily basal insulin, specifically to manage this titration period.

The clinical alert on hypoglycemia in T2D Patients treated with Awiqli tended to have a greater incidence of hypoglycemia than daily comparators in some study arms, while in insulin-naive patients the rates were comparable or favorable. The key implication is that icodec requires more careful patient selection and titration guidance when used as a switch therapy versus a treatment initiation therapy. In T2D specifically, the clinical concern about hypoglycemia is lower than in T1D: T2D patients retain some endogenous insulin secretion and have counterregulatory responses that protect against severe hypoglycemia. The T1D population, where hypoglycemia was more concerning and drove the CRL, is not included in the current U.S. approval. For T2D, the FDA and the ONWARDS investigators judged the benefit-risk profile favorable.

Practical Use: Dosing, Switching, and Missed Doses

The U-700 concentration: what this means practically

Awiqli is a U-700 formulation, 700 units per mL, compared to the U-100 (100 units per mL) that most daily basal insulins use. This higher concentration is what allows a full week’s worth of insulin to be administered in a single manageable injection volume. It means that icodec is not substitutable unit-for-unit with daily insulins: a week’s dose of icodec is roughly equivalent to 7 days of the total daily dose, not a single daily dose. Careful dose calculation is required at initiation and when switching.

Starting doses and switching guidance

Patient situation	Starting approach
Insulin-naive	Start at 70 units once weekly. Titrate based on fasting blood glucose, adjusting no more than every 2 weeks.
Switching from daily basal insulin	Start at 20% higher than previous total daily basal dose, given once weekly. This accounts for the accumulation phase.
Adding to GLP-1 or oral agents	Start at 70 units weekly (same as insulin-naive). Be alert to enhanced glucose-lowering from the combination.
Patients on basal-bolus regimens	Switch based on individual assessment; the ONWARDS 4 data supports the transition in this population.

Missed dose flexibility: a genuine practical advantage

One underappreciated benefit of icodec’s long half-life is missed-dose forgiveness. Because the drug accumulates in the albumin depot and releases continuously, a missed or shifted dose is less clinically consequential than with daily insulin. The prescribing information states that if a dose is missed, it can be administered up to 3 days (72 hours) before or after the scheduled day. After administration, resume the original once-weekly schedule. This flexibility directly addresses one of the practical frustrations of daily insulin, the anxiety around a forgotten or delayed dose.

Administration

Awiqli is administered subcutaneously once weekly on the same day each week, using the Novo Nordisk FlexTouch prefilled pen. It is available in three pen sizes: 700 units per 1 mL, 1050 units per 1.5 mL, and 2100 units per 3 mL. It must not be administered intravenously, intramuscularly, or via insulin pump, and must not be mixed with other insulin products.

Safety: What the Prescribing Information Covers

The safety profile of Awiqli is broadly consistent with the basal insulin class, with the nuances around hypoglycemia and titration already discussed above.

Common adverse reactions: hypoglycemia, injection site reactions (redness, swelling, itching), lipodystrophy (skin thickening or pitting at injection sites), pruritus, rash, peripheral edema, weight gain.

Serious risks:

Severe hypoglycemia
Serious hypersensitivity reactions including anaphylaxis, angioedema, urticaria, and swelling of face and lips
Hypokalemia (low potassium, which may affect heart rhythm)

Thiazolidinediones (TZDs): Use with pioglitazone or rosiglitazone increases the risk of fluid retention and potential heart failure exacerbation. Monitor for signs of heart failure when co-prescribing.

Acute illness and fasting: During illness or significant changes in eating, blood glucose monitoring frequency should increase and dose adjustments may be needed. The long half-life means that missed or delayed doses are tolerated, but significant metabolic stress (surgery, serious illness) requires closer glucose monitoring.

Not indicated for: ketoacidosis treatment, diabetic ketoacidosis, use via intravenous or intramuscular routes, or use with insulin infusion pumps.

Why Injection Frequency Matters More Than It Might Seem

The clinical significance of moving from daily to weekly injections goes beyond convenience. The diabetes literature on insulin adherence is consistent: injection burden is one of the leading modifiable barriers to insulin initiation and continuation. “Psychological insulin resistance,” the phenomenon in which patients delay or avoid starting insulin despite clinical need, is documented in 20 to 30% of people with T2D who are recommended insulin.

Insulin omission is also common among those already on therapy: studies estimate that 20 to 50% of patients on daily basal insulin skip doses at least occasionally, with higher rates among those with greater injection frequency or complex regimens. Each omitted dose represents a period of inadequate glycemic coverage. Sustained omission accelerates the development of diabetes complications.

Once-weekly dosing does not eliminate these barriers, but it substantially reduces the number of opportunities for omission and lowers the daily psychological overhead of managing insulin therapy. Whether this translates into measurably better real-world outcomes beyond what the controlled trials demonstrated will only be known from post-marketing evidence. But the mechanistic argument is sound.

Availability and Global Status

Novo Nordisk has indicated Awiqli will be available at U.S. pharmacies in the second half of 2026. The drug has already been approved in the European Union, Canada, Australia, Japan, Switzerland, and more than a dozen other countries, in many of those markets for both type 1 and type 2 diabetes. The U.S. approval is limited to type 2 diabetes.

Pricing and formulary coverage have not been announced for the U.S. market at time of writing. Patients and clinicians should check with their insurance provider and Novo Nordisk’s patient support resources as the launch approaches. For patients on insulin experiencing cost barriers, the Novo Nordisk patient assistance program and the NeedyMeds database are useful starting points.

For related HED coverage on diabetes treatment advances and access, see our posts on the FDA approval of the first generic dapagliflozin tablets and the approval of Foundayo (orforglipron), the first oral GLP-1 pill for weight management without food or water restrictions.

Sources

FDA approval and Novo Nordisk press release: FDA approves Novo Nordisk’s Awiqli (insulin icodec-abae), the first and only once-weekly basal insulin treatment for adults with T2D. March 26, 2026. prnewswire.com.

HCPLive coverage: FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes. hcplive.com. March 2026.

Patient Care Online coverage: FDA Approves Once-Weekly Basal Insulin for Adults With Type 2 Diabetes. patientcareonline.com. March 2026.

Consultant360: FDA Approves Awiqli (Insulin Icodec-Abae) as Once-Weekly Basal Insulin. consultant360.com. March 2026.

ONWARDS 1 (NEJM): Rosenstock J et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. NEJM. 2023;389(16):1533. doi:10.1056/NEJMoa2310221

ONWARDS 2 (Lancet Diabetes Endocrinol): Philis-Tsimikas A et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in basal insulin-treated T2D (ONWARDS 2). Lancet Diabetes Endocrinol. 2023.

ONWARDS 3 (JAMA): Lingvay I et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive T2D: ONWARDS 3. JAMA. 2023;330(3):228-237.

ONWARDS 4 (Lancet): Mathieu C et al. Switching to once-weekly icodec vs once-daily glargine U100 in basal-bolus insulin-treated T2D (ONWARDS 4). Lancet. 2023.

ONWARDS 1 trial registration: NCT04508660. ClinicalTrials.gov.

ONWARDS 2 trial registration: NCT04771052. ClinicalTrials.gov.

ONWARDS 3 trial registration: NCT04832711. ClinicalTrials.gov.

ONWARDS 4 trial registration: NCT04835493. ClinicalTrials.gov.

Awiqli prescribing information: Awiqli (insulin icodec-abae) injection 700 units/mL. Novo Nordisk. 2026.

ADA Standards 2026: American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2026. Diabetes Care. 2026;49(suppl 1).

Time in Range reference: Battelino T et al. Clinical targets for CGM data interpretation: recommendations from the international consensus on time in range. PMC6240448.

Insulin adherence literature: Insulin Adherence and Injection Burden in T2D. PMC7716091.

Basal insulin overview: Basal Insulin. StatPearls. NCBI.

Albumin physiology: Albumin. StatPearls. NCBI.

Hypoglycemia: Hypoglycemia. StatPearls. NCBI.

Hypokalemia: Hypokalemia. StatPearls. NCBI.

Diabetic ketoacidosis: Diabetic Ketoacidosis. StatPearls. NCBI.

Diabetes complications: Preventing Diabetes Complications. NIDDK.

Patient resources: Novo Nordisk patient support | NeedyMeds | ADA Standards of Care | CDC Diabetes

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Insulin therapy requires individualized dosing and monitoring. Any changes to insulin regimen should be made in close consultation with your diabetes care provider.

Stimulants and Atomoxetine Have Defined ADHD Treatment for Decades. Simtriyo Is the First Drug Approved That Simultaneously Targets All Three Monoamine Neurotransmitter Systems. Here Is Why That Matters.

ROS1-Positive Lung Cancer Tends to Affect Younger, Non-Smoking Patients. First-Line TKI Therapy Works (Until It Doesn’t). Jideytro Is Now the First Approved Option When It Stops Working.

Retevmo Received Accelerated Approval for RET Fusion-Positive Solid Tumors in 2022 on Response Rate Data. On July 14, 2026, the FDA Confirmed the Clinical Benefit Was Real. Here Is What That Conversion Means.

Leqembi Has Changed What Is Possible in Early Alzheimer’s Disease. Until Now, Every Dose Required a Clinic Visit and an IV Line. That Changed on July 13, 2026.

For 25 Years, Cisplatin-Based Chemotherapy Before Bladder Removal Was the Only Regimen Shown to Improve Survival in Muscle-Invasive Bladder Cancer. A New Phase 3 Trial Just Surpassed It.

Seasonal Allergic Rhinitis in School-Age Children Is One of the Most Undertreated Conditions in Pediatrics. Ryaltris Just Became the First Fixed-Dose Antihistamine-Steroid Nasal Spray Approved for Children as Young as Six.

Von Willebrand Disease Is the Most Common Inherited Bleeding Disorder in the World. In Young Children With Severe Disease, Prophylactic Treatment Has Lacked Any FDA-Approved Option Until Now.

The World’s First CRISPR Gene Therapy Was Approved in 2023 for Patients 12 and Older. On July 1, 2026, It Became Available to Children as Young as Age Two. Here Is What That Means.

PCSK9 Inhibitors Have Been Among the Most Effective Cholesterol Drugs Ever Developed. They Have Also Required Injections Every Two to Four Weeks. Lipfendra Is the First One That Is Just a Pill.

Sixty Percent of HR+/HER2- Breast Cancer Patients Who Progress on CDK4/6 Inhibitors Have PIK3CA Wild-Type Disease. Until Now, They Had No Approved Targeted Therapy. Revtorpyk Just Changed That.

Stimulants and Atomoxetine Have Defined ADHD Treatment for Decades. Simtriyo Is the First Drug Approved That Simultaneously Targets All Three Monoamine Neurotransmitter Systems. Here Is Why That Matters.

ROS1-Positive Lung Cancer Tends to Affect Younger, Non-Smoking Patients. First-Line TKI Therapy Works (Until It Doesn’t). Jideytro Is Now the First Approved Option When It Stops Working.

Retevmo Received Accelerated Approval for RET Fusion-Positive Solid Tumors in 2022 on Response Rate Data. On July 14, 2026, the FDA Confirmed the Clinical Benefit Was Real. Here Is What That Conversion Means.

Leqembi Has Changed What Is Possible in Early Alzheimer’s Disease. Until Now, Every Dose Required a Clinic Visit and an IV Line. That Changed on July 13, 2026.

For 25 Years, Cisplatin-Based Chemotherapy Before Bladder Removal Was the Only Regimen Shown to Improve Survival in Muscle-Invasive Bladder Cancer. A New Phase 3 Trial Just Surpassed It.

Von Willebrand Disease Is the Most Common Inherited Bleeding Disorder in the World. In Young Children With Severe Disease, Prophylactic Treatment Has Lacked Any FDA-Approved Option Until Now.

The World’s First CRISPR Gene Therapy Was Approved in 2023 for Patients 12 and Older. On July 1, 2026, It Became Available to Children as Young as Age Two. Here Is What That Means.

PCSK9 Inhibitors Have Been Among the Most Effective Cholesterol Drugs Ever Developed. They Have Also Required Injections Every Two to Four Weeks. Lipfendra Is the First One That Is Just a Pill.

Sixty Percent of HR+/HER2- Breast Cancer Patients Who Progress on CDK4/6 Inhibitors Have PIK3CA Wild-Type Disease. Until Now, They Had No Approved Targeted Therapy. Revtorpyk Just Changed That.

Topical Steroids Cannot Be Used Long-Term on a Two-Year-Old’s Face or Skin Folds. For Children That Young With Plaque Psoriasis, There Has Been Almost Nothing Else. Zoryve Cream Just Changed That.